

INDEX TO VOLUME 30

Author Index

Abal, A. T., S201
 Abbott, M., 949
 Abele-Horn, M., 405
 Abi-Hanna, P., 630
 Aboulafia, D. M., 826
 Acar, J., 454
 Acosta, E. P., S151
 Active Bacterial Core Surveillance Team, 212
 Adult and Adolescent Spectrum of HIV Disease Project Group, 241, 955
 Agbemazdo, B., 229
 Agnew, K., 901
 Aguero-Rosenfeld, M. E., 545
 AIDS Cooperative Treatment Groups, 47
 Akesson, A., 585
 Akiti, T., 300
 Alanen, A., 363
 Alangaden, G., 984
 Alcantára, R., 400
 Aliaga, L., 461
 Allen, S. D., 141
 Almela, M., 368
 Alonso-Pulpón, L., 603
 Alvarez, A., 400
 Alzieu, M., 209
 Amir, J., 500
 Amoudy, H. A., S201
 Ampel, N. M., 658
 Amstey, M. S., 237
 Andersen, P., S201
 Anderson, P. L., S151
 Ando, Y., 185
 Andrade, R. J., 400
 Angarano, G., 831
 Anunnatsiri, S., 29
 Aoki, F. Y., 549
 Arbeit, R. D., S309
 Arduino, M. J., 35
 Areff, D., 433
 Armenian, H. K., 946
 Arribas, J. R., 915
 Arya, S. C., 988
 Asch, S. M., S85, 293
 Ascioglu, S., 41
 Asensio, A., 55
 Ashkin, D., 779
 Ashley, R. L., 839
 Asnis, D. S., 413
 Atkins, B., 942
 Avšić-Županc, T., 987
 Baboo, K. S., S309
 Baddour, L. M., 87
 Baden, L., 609
 Baker, C. J., 276, 282
 Balotta, C., 962
 Baquero, F., 55
 Baraldès, M. A., 615
 Baran, J., Jr., 396
 Barbour, J. D., 504
 Barlam, T. F., 622
 Barr, D., S85
 Barreiros, G., 300
 Barrera, A., 461
 Barrio, J. L., 615
 Barrio, V. R., 408
 Bartlett, M. S., 141
 Bartoloni, A., 210
 Bartt, R., 229
 Bashore, T., 633
 Bass, C. R., 387
 Bassetti, D., 947
 Bassetti, M., 947
 Baumgarten, K., 639
 Baxter, R., 406
 Beavis, K. G., 384
 Belmaker, I., 319
 Belshe, R. B., S217
 Beni, S., 825
 Benilevi, D., 982
 Benito, L. M., 976
 Bennett, J. E., 696
 Berenguer, J., 182
 Bergström, T., 529
 Bernard, E., 201
 Bernardin, G., 201
 Bertino, J. S., Jr., 440
 Bertolli, J., S5
 Bettelheim, K. A., 984
 Bhargava, A., 954
 Bianchine, P. J., 35
 Biasoli, I., 300
 Bilenko, N., 419
 Binswanger, I. A., 579
 Bjerke, R., 582
 Bjerre, A., 643
 Blanchard, J. F., 946
 Blanco, M., 976
 Blower, S. M., S316
 Bluthenthal, R. N., 579
 Blythe, D., 61
 Bodey, G. P., 851
 Böhn, I., 606
 Boissy, C., 201
 Bolte, E. R., 213
 Boscia, D., 831
 Bossi, P., 227
 Bossolasco, S., 95
 Böttger, E., 210
 Boutin, P., 540
 Bouza, E., 306
 Boylan, A., 569
 Bozette, S. A., S85
 Bradsher, R., 688
 Bradsher, R. W., Jr., 679
 Brambilla, A. M., 95
 Brandtzæg, P., 643
 Brankovic, L. E., 195
 Breiman, R. F., 71, S199, 520
 Brennan, M. J., S247
 Bricaire, F., 227
 Brown, A. E., 625, 819
 Brown, B. A., 288
 Brown, G. H., 440
 Brown, J. W., III, 605
 Brown, K. E., 569
 Brown, R. M., S217
 Brown, T. L., 893
 Bruckner, D. A., 195, 790
 Brundage, R. C., S151
 Brunel, F., 940
 Brunham, R. C., 946
 Bryant, J., 100, 122
 Bryant, R. E., 349
 Bucher, H. C., 602
 Buck, G., 191
 Burroughs, M., 857
 Busch, D. F., 815
 Bustamante, B., 65
 Busutil, R. W., 790
 Bwayo, J. J., 486
 Byl, B., 838
 Cabellos, C., 239
 Cadrobbi, P., 619
 Cairns, L., 61
 Camargo, R., 400
 Campbell, G. D., Jr., 679
 Cantón, R., 55
 Capiluppi, B., 962
 Carbonara, S., 831
 Carbonaro, C., 545
 Carmoi, T., 840
 Carneskg, J., 342
 Carr, A., S135
 Carrette, P., 840
 Carson, L. A., 35
 Carter, L. G., 893
 Cartoni, D., 825
 Casari, S., 95
 Casassus, P., 41
 Casellas, J. M., 473
 Castro, S. D., 825
 Catanzaro, A., 658
 Cattelan, A. M., 619
 Caumes, E., 227, 811
 Cave, M. D., 356
 Cegielski, P., 288
 Celum, C. L., 261
 Cerón, A., 981
 Cetron, M. S., 71, 520
 Chaiprasert, A., 29
 Chakraborty, H., 742
 Chambers, M. A., S283, S299
 Chambers, S. T., 382
 Chan, R. M. T., 882
 Chan, W.-m., 882
 Chanbancherd, P., 819
 Chandrasekar, P. H., 403, 984
 Chang, F. Y., 322
 Chapman, S. W., 679, 684
 Chechko, S., 954
 Chen, T.-W., 823
 Cheng, V. C. C., 882
 Cherry, J. D., 534
 Chesney, M. A., S171
 Chetchotisakd, P., 29, 877
 Chevalier, B., 840
 Chez, M. G., 213
 Chiaramondia, M., 947
 Chien, J. W., 146
 Chintu, C., S309
 Chiu, C.-H., 239
 Chocarro Martinez, A., 234
 Choonthakarn, C., 29
 Chou, Y.-H., 823
 Chowfin, A., 969
 Christensson, B., 585
 Christopher, G. W., 843
 Chuck, S. K., 433
 Cieslak, P. R., 515
 Cieslak, T. J., 843
 Cinque, P., 95
 Cinti, S. K., 511
 Ciocchini, M., 222
 Ciuffreda, D., 962
 Clark, C., 764
 Clark, N. M., 403
 Clark, R., 407
 Cleavinger, P. J., 176
 Clemons, K. V., 328
 Cloud, G., 47
 Cobo, J., 55
 Cobo-Soriano, R., 306
 Cockle, P. J., S291
 Coffin, S. E., 179
 Cohen, A. H., 500
 Cohen, J., 961
 Cohen, M. S., 736, 742
 Cohen, S. H., 952
 Cohn, S. E., 749
 Colin, D., 227
 Collado, A., 461
 Commander, N., S283
 Comstock, G. W., S250
 Conetta, R., 413
 Connolly, P., 877
 Conway, B., S130
 Cook, J. L., 444
 Cook, R. L., 406
 Coppola, S. J., 78
 Cordeiro, S. M., 78
 Cordero, E., 461

Corey, G. R., 633
 Corey, L., 261
 Cortés, C., 306
 Costa, D., 831
 Costello, C. N., 534
 Côté, H. C. F., S117
 Cotter, P. A., 534
 Crane, L. R., 511
 Cruceta, A., 392
 Culpepper, R. C., 843
 Cunha, B. A., 237
 Cunningham, A. L., 549
 Cunningham, E. T., 232
 Curley, G. V., 595
 Currier, J. S., S66
 Cynamon, M. H., S288
 Dagan, R., 319, 419
 D'Agostino, A. N., 349
 Dalovisio, J. R., 639
 d'Amati, G., 825
 Dance, D. A. B., 235
 Dankner, W. M., 356
 Darmstadt, G. L., 408
 Davidson, P., 293
 Davidson, R. N., 764
 Davies, A., S299
 Davis, C. E., 356
 Davis, T. E., 29
 Daza, R. M., 603
 Deckelbaum, R. J., 419
 Deeks, S. G., S177, 504
 Deep, A. E., 65
 De Groote, M. A., 87, 226, 582
 Del Bono, V., 947
 del Giudice, P., 201, 820
 Dellamonica, P., 201
 De Mauleon, P., 840
 Denison, E. K., 618
 Denning, D. W., 41, 696
 Dennis, D. T., 893
 De Pauw, B., 41
 Derchi, L. E., 947
 Derossi, A., 300
 DeSimone, J. A., 384
 DeStefano, M. S., S288
 Dhillon, S. S., 572
 Dickstein, B., 569
 Didier, C., 840
 Dillaha, J. A., 399
 Di Pietro, M., 962
 DiSalvo, A. F., 328
 Dismukes, W. E., 14, 19, 47,
 653, 662, 710
 Doern, G. V., 166
 Domingo, P., 615
 Donepudi, R., 629
 Dotevall, L., 410
 Dowell, S. F., 784
 Downey, M. S., 590
 Dummer, S., 696
 Durant, J., 201
 Dworkin, M. S., S5, 241, 955
 Ebinger, M., 606
 Edlin, B. R., 579
 Edwards, J. E., 662
 Eichenauer, E., 938
 Eitzen, E. M., Jr., 843
 Ekwall, E., 770
 Eliadis, K., 567
 Ellner, J. J., S279
 El-On, J., 419
 Emmanouilides, C., 790
 Engel, G., 215
 Engelmann, H., 342
 Epstein, J. S., 35
 Ernst, C., 986
 Eron, J. J., Jr., S160
 Eschelman, D. J., 384
 Eschenbach, D. A., 901
 Ettestad, P., 893
 European Organization for Re-
 search and Treatment of
 Cancer/Invasive Fungal In-
 fections Cooperative Group
 and the Intergroupe Français
 du Myélome, 41
 Evans, J., 820
 Evans, T. G., 608
 Evengård, B., 770
 Eykyn, S. J., 336
 Falagas, M. E., 567
 Falloon, J., 313
 Farley, M. M., 71, 520
 Farver, C. E., 595
 Fearon, W. F., 215
 Fedele, F., 825
 Feinberg, J., 749
 Feldman, P. A., 982
 Feray, C., 820
 Fernandez, M., 282
 Ferraro, M. J., 799
 Ferrieri, P., 276
 Feuilhade, M., 820
 Fichtenbaum, C. J., 749
 Figueiras, M. J., 988
 Filler, S. G., 662
 Fine, M. J., 520
 Fiore, A. E., 71
 Fiorell, M., 825
 Fiorentino, G., 831
 Fischer, T., 219
 Fish, D. N., 908
 Fitzgerald, E. A., 35
 Flack, N. P., 587
 Flanagan, A. M., 764
 Fleming, D. W., 515
 Fletcher, C. V., S151
 Flores, A. E., 276
 Fluit, A. C., 454
 Fong, I. W., 757
 Fong, M. W., 757
 Ford, B., 971
 Fouché, R., 201
 Fowler, V. G., Jr., 633
 Frame, P., 749
 Franco, S. M., 191
 Frank, A. L., 630
 Fraser, D., 419
 Frederick, T., S5
 Freedberg, K. A., S15, S85
 Frias, C., 576
 Friedman, M. S., 984
 Friesen, P. P., 946
 Fritz, C. L., 893
 Frontera, J. A., 374
 Fujisawa, H., 380
 Fukuda, S., 529
 Furrer, H., 943
 Furuta, Y., 529
 Gage, K. L., 893
 Galgiani, J. N., 658
 Gallart, M. T., 392
 Gallego, J. C., 603
 Gallis, H. A., 14
 Gallo, P., 825
 Gallucci, M., 223
 Galvão Reis, M., 78
 Garbutt, J. M., 466
 Garcia, F., 392
 Garcia Garcia, I., 234
 Garner, R., 736
 Gatell, J. M., 392
 Gathe, J. C., Jr., 491
 Gaydos, C. A., 719
 Gaydos, J. C., 719
 Gayowski, T., 322
 Gelberg, L., 293
 Gennaro, M. L., S243
 Gennesin, Y., 152
 Gerber, J. G., S123
 Gildenberg, P. L., 491
 Ginsberg, A. M., S199, S233
 Ginsberg, M. M., 618
 Giobbia, M., 223
 Girón, J. A., 461
 Gisbert, J. P., 976
 Giudici, B., 95
 Glassroth, J., S229
 Gnann, J. W., Jr., S72
 Goldman, M., 141
 Goldsmith, L. J., 191
 Goldwater, P. N., 984
 Gómez-Mateos, J., 461
 González-Diego, P., 55
 González-García, J. J., 915
 González Lopez, A., 234
 González-Serrano, M., 461
 Goodman, E. L., 234
 Goodnough, S., 425
 Goossens, H., 473
 Gorbach, S. L., 1
 Gori, A., 962
 Gornbein, J. A., 534
 Gottlieb, T., 942
 Gouveia, E. L., 78
 Gralon, J. D., 374
 Gradstein, S., 319
 Graham, J. V., 609
 Graham, R., 425
 Grant, R. M., 504
 Graybill, J. R., 47
 Graybill, R. J., 710
 Gredlein, C. M., 590
 Greer, R. W., 605
 Griffin, J. F. T., S223
 Griffith, D. E., 288
 Grimaldi, A., 831
 Grimont, F., 395
 Gross, P. A., S85
 Guarro, J., 988
 Guest, J. L., 410
 Gux, A.-C., 602
 Guglielminotti, J., 209
 Guglielmo, B. J., 205
 Guidet, B., 209
 Gupta, R., 454
 Gurgui, M., 615
 Gwaltney, J. M., Jr., 387
 Habbema, J. D. F., S309
 Hacini, J., 395
 Hagberg, L., 410
 Hagman, H. M., 349
 Hajjeh, R., 61, 684, 877
 Halachmi, S., 982
 Hall, B., 599
 Halvorsen, S., 643
 Hamill, R., 47, 688
 Hammarström, V., 342
 Hamrick, H. J., 627
 Han, S.-R., 219
 Handa, A., 569
 Handsfield, H. H., 839
 Hansen, N. C., 35
 Hanson, D. L., S5, 955
 Harbarth, S., 990
 Harel, L., 500
 Harrell, L., 870
 Harrigan, P. R., S117
 Harris, C., 198
 Harrison, L. H., 71, 648
 Haslett, P. A. J., 224, 540
 Hausdorff, W. P., 100, 122
 Hayden, F. G., 587
 Hayden, M. K., 630
 Hedlund, K. O., 770
 Heifets, L. B., 444
 Helmreich-Becker, I., 219
 Henderson, D. A., 926
 Hendley, J. O., 387
 Henning, K. J., 384
 Henry, D., 587
 Heraud, J. M., 188
 Herbrecht, R., 41
 Hernández-Albújar, S., 915
 Hernández-Quero, J., 461
 Heussel, C. P., 219
 Hewinson, R. G., S283, S291,
 S299
 Hickman, M. E., 282
 Hillier, S., 276
 Hindler, J., 790
 Hirsch, C. S., S279

Ho, J., 757
 Ho, P. L., 989
 Hocqueloux, L., 940
 Hoffman, I. F., 736, 742
 Hofmann, J., 520
 Hoft, D. F., S217, S257
 Holgado, W., 65
 Holland, F., 749
 Hollender, E. S., 779
 Holmberg, S., S5
 Holmes, K. K., S1, S15
 Holtgrave, D., S15
 Holtzer, C., 232
 Hommel, D., 188
 Hook, E. W., III, 540
 Hooke, J., 936
 Hooke, M., 936
 Hooper, D. C., 243
 Hooton, T. M., 901
 Horsburgh, C. R., Jr., S213
 Hsue, G., 534
 Huang, J. S., 504
 Huang, S. S., 504
 Huber, C., 219
 Huitt, G. A., 444
 Hukkanen, V., 363
 Hulin, A., 188
 Hurwitz, S., 540
 Imakita, M., 611
 Inglesby, T. V., 926
 Ishibashi-Ueda, H., 611
 Ito, Y., 185
 Jackson, L. A., 534
 Jacobs, R. A., 205
 Jacobson, K. L., 965
 Jacobson, M. A., 232
 Jaffe, H. W., S72
 Janci, J., 319
 Jarvis, W. R., 35, 270
 Jenkins, P. R., 723, 730, 736, 742
 Jenkins, R. A., 723, 730, 736
 Jenny-Avital, E. R., 409
 Jeronimo, S. M. B., 608
 Jiménez de Anta, M. T., 368
 Jirarattanapochai, K., 29
 Johnson, J. R., 234, 836, 838
 Johnson, P., 688
 Johnson, R. H., 658
 Johnson, W. D., Jr., 78
 Jones, D., 779
 Jones, J. L., S5
 Jones, K. C., 270
 Jones, M. E., 454
 Jonsson, G., 342
 Jorgensen, J. H., 71, 799
 Jubran, R. F., 569
 Judson, M. A., 696
 Juneau, J., 639
 Kahler, L., 425
 Kain, K. C., 401
 Kaiser, L., 587
 Kakuda, T. N., S151
 Kan, V. L., 621, 696
 Kao, A., 61
 Kaplan, J. E., S1, S5, S15
 Karagas, M. R., S309
 Karchmer, A. W., 14, 19, 609
 Kärnell, A., 770
 Kateiva, J., 639
 Kauffman, C. A., 14, 19, 403, 679, 684, 688
 Kaufman, L., 61
 Kaul, D. R., 511
 Kavlick, M. F., 313
 Kawabata, H., 529
 Kazanjian, P. H., 511
 Keene, O., 587
 Keiser, P., 949
 Kelkar, S., 630
 Keller, M., 599
 Kelly, J. J., 985
 Kern, V. L., 195
 Keysary, A., 214
 Keystone, J. S., 401
 Khatib, R., 396
 Khawplod, P., 218
 Kierulf, P., 643
 Kim, J. H., 491
 Kimura, H., 185
 Kitahata, M. M., S85
 Kite-Powell, K., 221
 Klein, D. L., S302
 Klock, C., 122
 Klugman, K. P., 473
 Knowles, L., 293
 Ko, A. I., 78
 Ko, W.-C., 473
 Kobayashi, J., 61
 Koehler, H. H., 219
 Kohler, R., 629
 Kolczak, M. S., 71
 Koletar, S., 749
 Kontaxis, A., 567
 Kontoyiannis, D. P., 851
 Kortepeter, M. G., 843
 Kosek, J. C., 215
 Kral, A. H., 579
 Kraus, D. H., 625
 Kreiss, J., 486
 Kroebel, A., 790
 Krohn, M. A., 276
 Kroll, J. S., 624
 Krone, M. R., 261
 Kropf, P., 764
 Kucia, M. L., 146
 Kumari, P., 621
 Kuritzkes, D. R., 256
 Kursh, E. D., 595
 Labarca, J. A., 195
 Lacey, C. J., 549
 Lacroix, C., 820
 LaFon, S., 313
 Lagergren, Å., 770
 Lam, L. L., 221
 Lamas, C. C., 336
 Lane, H. C., 313
 Larsen, R. A., 710
 Larwood, T. R., 612
 Lasheras, D., 55
 Lassak, M., 406
 Laut, J., 198
 Lauzurica, R., 576
 Lavreys, L., 486
 Lazzarin, A., 95, 962
 Leber, A. L., 195
 Leder, K. S., 622
 LeDoux, M. S., 211
 Lee, C.-C., 823
 Lee, C.-H., 141
 Lee, J. Y., 14, 19
 Lee, M. B., 401
 Lee, M.-L. T., 276
 Leib, S. L., 837
 Lein, A. D., S309
 Lellouche, N., 209
 Li, H., 176
 Li, J. S., 633
 Libshitz, H. I., 965
 Lietman, T., S316
 Lin, T.-Y., 239
 Linde, A., 342
 Lindgren, M. L., S5
 Lindholm-Levy, P., 444
 Lippek, F., 938
 Lipton, A., 534
 Lisziewicz, J., S193
 Littenberg, B., 466
 Ljungman, P., 342
 Lo, B., 757
 Lôbo, T. S., 78
 Löfdahl, S., 770
 Lopez-Garrido, M. J., 400
 Lori, F., S193
 Lortholary, O., 41
 Lotrič-Furlan, S., 987
 Loutit, J. S., 215
 Lowrie, D., S283
 Lowther, S. A., 955
 Loyd, J., 688
 Luban, N. L. C., 569
 Luber, A. D., 205
 Lucena, M. I., 400
 Lüke, W., 95
 Ma, E. S. K., 882
 Mackin, G. A., 226
 Madeb, R., 982
 Madi, N. M., S201
 Madnick, E. G., 349
 Madon, E., 222
 Maeurer, M. J., 219
 Malkin, M., 625
 Mallolas, J., 182
 Manavathu, E., 984
 Mandaliya, K., 486
 Mandell, W., 613
 Mansfrin, V., 210
 Mangi, R., 14
 Mangum, M. E., 627
 Manion, D. J., 313
 Mann, S., 942
 Manneke, B., 606
 Mantella, A., 210
 Marcinak, J. F., 630
 Marco, F., 368
 Margolis, T. P., 232
 Marino, I. R., 322
 Marinus, A., 41
 Marmont, A., 222
 Marra, C. M., 540
 Marsh, P. D., S299
 Marshall, B. G., 764
 Marston, B., 410
 Martin, H. L., Jr., 486
 Martin, J. W., 936
 Martinez, J. A., 368
 Martinez-Murcia, A., 988
 Martinie, C., 840
 Martino, S., 222
 Martinoli, C., 947
 Mast, E. E., S77
 Masur, H., S1, S15, 313
 Maury, E., 209
 Mawhorter, S. D., 595
 Max, B., S96
 May, H., 198
 Maytan, M., 922
 Mazzarello, G., 947
 McArthur, J. C., 540
 McCombs, S. B., 241
 McCormack, J. G., 473
 McCullough, M. J., 328
 McCune, J. M., 504
 McDermott, L., 870
 McKee, K. T., Jr., 723, 730, 736, 742
 McKellar, P. P., 816
 McKinsey, D. S., 14, 19, 87, 688
 McMurray, D. N., S210
 McNeil, S. A., 403
 McPhaul, L., 599
 Meier, A., 901
 Melnick, D. A., S85
 Meneghetti, F., 619
 Meng, Y.-X., 221
 Mensa, J., 368
 Merino, M. D., 461
 Metlay, J. P., 520
 Mick, N., 633
 Miedouze, M., 395
 Miller, L. G., 293
 Miller, S., 545
 Miller, W. C., 742
 Mindel, A., 549
 Minozzi, C., 820
 Mirels, L. F., 349
 Miro, J. M., 392
 Mirón, M., 397
 Mitchell, P. S., 176
 Mitchell, S., 969
 Mitsuya, H., 313

Mizock, B. A., 229
 Mohan, U. R., 624
 Mohapatra, S., 473
 Mokrzycki, M. H., 198
 Monno, L., 831
 Monsuez, J.-J., 820
 Montaner, J. S. G., S143
 Montoya, J., 981
 Mootsikapun, P., 29
 Morandini, B., 962
 Moreau, P., 41
 Moreira, A. L., 224
 Moreno-Martinez, A., 368
 Morin, P., S309
 Morishima, T., 185
 Moroney, J. F., 71
 Morris, A. J., 870
 Morrison, V. A., 696
 Morse, A., 407
 Moscona, A., 857
 Mosher, A., 14
 Moylett, E. H., 282
 Mukherji, S. K., 627
 Mulazimoglu, L., 473
 Mulholland, K., S206
 Müller, I., 764
 Mundy, L. M., 466
 Muñoz, I., 368
 Muñoz, P., 306
 Muñoz, R. M., 603
 Murakami, T., 185
 Murali, R., 613
 Murdoch, D. R., 382
 Murphy, D. T., 288
 Murphy, R. L., S95
 Murray, K., 764
 Musher, D. M., 25
 Mustafa, A. S., S201
 Mwinga, A., S309
 Mygind, N., 387
 Mylotte, J. M., 425
 Nadelman, R. B., 545, 818
 Naggan, L., 419
 Nannis, E. D., 723, 730, 736
 Narita, M., 779, 405
 Naso, A., 619
 National Institute of Allergy and Infectious Diseases Mycoses Study Group, 14, 19, 47
 Nativ, O., 982
 Nauschuetz, W. F., 534
 Ndinya-Achola, J. O., 486
 Nettles, R., 633
 Nevin, T., 540
 Ng, V. L., 504
 Ng, Y.-Y., 823
 Nguyen, M. H., 870
 Nichterlein, T., 606
 Nieman, R. E., 985
 Nolasco, D., 65
 Nomura, T., 380
 Nowakowski, J., 545
 Nucci, M., 300
 Nuño, E., 461
 Öberg, G., 342
 O'Brien, K. L., 784
 O'Brien, W. A., S185
 Offenstadt, G., 209
 Oftung, F., S201
 Ogbolu, C., 954
 Ogbuokiri, T., 407
 Ohtani, F., 529
 Oliver, A., 55
 Ono, C. M., 534
 Onorato, I. M., 617
 Orloski, K. A., 893
 Ormerod, L. D., 479
 O'Toole, T., 926
 Otsuka, F., 380
 Ou, J. T., 239
 Øvstebø, R., 643
 Owens, D. K., 157
 Pachón, J., 461
 Pages, C. L., 940
 Pajares, J. M., 976
 Palacios, M., 55
 Paletta, D., Jr., 205
 Palmsano, J., 198
 Pancharoen, C., 218
 Pandian, N. G., 825
 Pankey, G. A., 696
 Panosian, C., 816
 Panzer, H., 19
 Papagno, L., 962
 Pape, W. J., 893
 Pappagianis, D., 61
 Pappas, P. G., 65, 662, 679, 710
 Paradise, M., 261
 Paradiso, P. R., 100, 122
 Park, P., 328
 Passeron, J., 820
 Pastore, G., 831
 Paterson, D. L., 322, 473
 Patterson, J. E., 71
 Patterson, T. F., 696
 Patton, D. L., 901
 Pau, C.-P., 221
 Paupksen, K., 342
 Pavlin, J. A., 843
 Pearson, R. D., 608
 Peeling, R., 946
 Pegues, D. A., 195
 Pellett, P. E., S72, 221
 Peña, J. M., 915
 Pérez-Díaz, J. C., 55
 Perfect, J. R., 710
 Pericas, R., 615
 Perkins, B. A., 212
 Perla, E. N., 935
 Perrin, C., 201
 Persing, D. H., 176
 Petit, D., 840
 Phan, H. M., 25
 Phanuphak, P., 218
 Phillips, C. D., 387
 Phillips, P., 971
 Pick, N., 214
 Pinel, C., 820
 Pinheiro, R. M., 78
 Piscitelli, S. C., S15, 313
 Pitchenik, A. E., 779
 Pitlik, S., 240
 Plana, M., 392
 Platt, R., 276
 Plotkin, S. A., 4
 Pontali, E., 947
 Popovic, T., 212
 Porat, N., 319
 Potasman, I., 214
 Pottage, J., 749
 Pourriere, M., 840
 Powderly, W. G., 47, 710, 749
 Poza, G., 981
 Pretolesi, F., 947
 Puklin, J. E., 479
 Pulcheri, W., 300
 Pumarola, T., 392
 Quinlisk, P., 784
 Quinn, J. P., 630
 Quinn, T. C., 719
 Raad, I., 965
 Rabalais, G. P., 191
 Raber, S. R., 433
 Rabkin, C. S., 762
 Radziwill, A. J., 602
 Rahmani, D., 952
 Ramanathan, J., 396
 Raz, R., 152
 Redondo, C., 981
 Reed, S. L., 959
 Regnery, H., 784
 Reichler, M. R., 617
 Reis, J. N., 78
 Reller, L. B., 165
 Rensch, M. A., 276, 282
 Replogle, M. L., 515
 Reppen, M. L., 270
 Rex, J. H., 662
 Reyes, M. P., 479
 Reynolds, P. J., 893
 Rhodes, L. V. III, 582
 Rhodes, S., S291
 Ribeiro Dourado, C. M., 78
 Ribera, J. M., 576
 Ricaurte, J. C., 613
 Richart, C., 397
 Rigoli, R., 223
 Riley, L. W., 78
 Rimland, D., 410
 Rinaldi, M. G., 349
 Rinaldo, C. R., 406
 Riser, L., 47
 Rivero, A., 461
 Rocha, H., 78
 Rodrigo, L., 400
 Rodriguez-Créixems, M., 306
 Rodriguez-Tudela, J. L., 981
 Rodvold, K. A., 433
 Rogers, M., 313
 Rollo, M. A., 831
 Rolston, K. V. I., 851, 965
 Romero, M. L., 174
 Ros, P., 55
 Rosenfeld, S., 152
 Rosen Krands, I., S201
 Rosenstein, N. E., 212
 Rotschafer, J. C., 440
 Rottensterich, E., 152
 Rouleau, D., S143
 Rowe, J. R., 843
 Royo, A., 915
 Rudich, H., 500
 Ruhnke, M., 938
 Ruiz, J., 981
 Ruth, A., 179
 Ruxrungham, K., 218
 Ryan, T., 633
 Rybold, D. J., 579
 Rzotkiewicz, S., 214
 Saag, M. S., 47, 710, 749
 Sadler, B., 313
 Safdar, A., 625
 Sagui, E., 840
 Sahouri, M. J., 479
 Sakaguchi, L. K., 534
 Salata, R. A., 146
 Salgado, K., 78
 Salmerón, J., 400
 Salmon, J. E., 25
 Sampson, B. A., 413
 Sánchez, F., 368
 Sanders, J. W., 936
 Sandler, R. H., 213
 Sapkas, G., 567
 Saracco, A., 962
 Sarosi, G., 688
 Sax, P. E., 511
 Scarparo, C., 210
 Scheckler, W. E., 270
 Schiller, G. J., 236
 Schmidt, D., 606
 Schmitz, F.-J., 454
 Schmitz, J. L., 736
 Schreckenberger, P. C., 630
 Schrift, M. J., 213
 Schuchat, A., 71
 Schumacher, U. K., 606
 Schwartz, B., 784
 Schwebke, J. R., 986
 Scott, L. L., 549
 Scotton, P. G., 223
 Searle, J., 938
 Seeff, L. B., S77
 Segovia, J., 603
 Sellier, P., 820
 Sellman, J., 784
 Sen, P., 954
 Seña, A. C., 742
 Sexton, D. J., 633
 Shaban, F., S201
 Shah, S. S., 179

Sharkey, P. K., 14
 Shatsky, S., 349
 Shaw, R. J., 764
 Shen, C., 946
 Sherer, R., S96
 Sherman, D. S., 908
 Shimoni, Z., 240
 Shinnick, T. M., S276
 Shiomi, M., 185
 Shiraki, K., 611
 Shoen, C. M., S288
 Shutt, K., 877
 Siakavellas, E. C., 567
 Siber, G. R., 100, 122
 Siddiqui, A. H., 174
 Siegman-Igra, Y., 986
 Silva, J., Jr., 952
 Silveira, F., 300
 Silverman, M. L., 590
 Simarro, E., 981
 Simpson, G., 540
 Singh, N., 322
 Sirvent, J. J., 397
 Sisson, B. A., 191
 Siton, Y., 319
 Sivak, S., 545
 Sjölin, J., 342
 Skiest, D. J., 949
 Smith, A. L., 35
 Smith, D. S., 444
 Smith, E. M., 270
 Smith, H., 582
 Smith, J. W., 141
 Smith, T. F., 176
 Snider, D. E., Jr., S271
 Snydman, D. R., 870
 Sobel, J. D., 14, 19, 47, 652,
 662, 710
 Solano, T., 942
 Sorza, C., 300
 Soriano, A., 368
 Soriano, E., 368
 Sousa, A. Q., 608
 Spanish Cidofovir Study
 Group, 182
 Spector, N., 300
 Spell, D. W., 605
 Spira, T. J., 221
 Spruance, S. L., 549
 Squier, C., 322
 Sriskandan, S., 961
 Srugo, I., 982
 Stambaugh, J. J., 779
 Stamey, F. R., 221
 Stamm, W. E., 152, 901
 Stanberry, L. R., 268, 549
 Stanley, H., 232
 Stapleton, A. E., 901
 Stefanova, R., 356
 Stein, J. D., 893
 Steiner, F., 629
 Stevens, D. A., 328, 349, 658,
 696
 St. George, K., 406
 Stocker, S. A., 212
 Stoeckli, T. C., 226
 Stoler, Z., 152
 Stone, F., 954
 Straussberg, R., 500
 Strle, F., 987
 Suárez-Leoz, M., 306
 Sugar, A. M., 14
 Sulkowski, M. S., S77
 Svensson, L., 770
 Svenungsson, B., 770
 Swaminathan, A., 954
 Swiss HIV Cohort Study, 943
 Symmans, W. F., 224
 Szurgot, J. G., 605
 Tabet, S. R., 261
 Tachdjian, R., 534
 Talarmin, A., 188
 Tambosis, E., 942
 Tambussi, G., 962
 Tancik, C. A., 399
 Tang, W. M., 989
 Tang, X., 141
 Tang, Y. J., 952
 Tang, Y.-W., 176
 Tantawichien, T., 218
 Tarrand, J., 965
 Tascon, R., S283
 Tasker, S., 87
 Tateishi, T., 380
 Tavares-Neto, J., 78
 Teira, R., 965
 Teixeira, A. A., 413
 Teixeira, M. J., 608
 Tellez, I., 65
 Temoshok, L. R., 723, 730
 Tenover, F. C., 212
 Territo, M. C., 195, 790
 Thielking, P., 608
 Thisykorn, U., 218
 Thomas, C., 19
 Thomas, D. L., S77
 Thompson, M. L., 486
 Thwin, S. S., 901
 Thys, J.-P., 838
 Tice, A., 839
 Tight, R., 969
 Tiu, C.-M., 823
 Tokars, J. I., 35, 270
 Tonon, E., 223
 Torres, J., 141
 Torres-Tortosa, M., 461
 Tortoli, E., 210, 831
 Tosteson, A. N. A., S309
 Tovo, P.-A., 222
 Toy, C., 757
 Trenholme, G. M., 473
 Trevenzoli, M., 619
 Trick, W. E., 270
 Tsang, T. H. F., 618
 Tsiodras, S., 609
 Tucker, R. M., 349
 Tvaroha, S., S309
 Ubol, P. N., 29
 Ubolyam, S., 218
 Ullmann, A. J., 219
 US Public Health Service/Infectious Diseases Society of America Prevention of Opportunistic Infections Working Group, S29
 Vachon, F., 940
 Vaglia, A., 223
 Vail, G., 629
 Valway, S. E., 617
 van der Horst, C., 47, 540, 749
 Van Dyke, R., S15
 Vaquero, M., 576
 Vayre, F., 820
 Vaz, B., 95
 Vazquez, G., 615
 Vazquez, J. A., 14, 19
 Vázquez, J. J., 915
 Venczel, L. V., 618
 Ventrapragada, M., 466
 Verhoef, J., 454
 Vidal, C., 392
 Vidal, F., 397
 Vila, N., 981
 Villanueva, A. V., 479
 Vincent, J. M., 534
 Vittecoq, D., 820
 Vogel, F. R., S266
 Vogel, S., 313
 Vold Pepper, P., 157
 Von Gottberg, A., 473
 von Reyn, C. F., S309
 Vordermeier, H. M., S283, S291
 Vugia, D. J., 618
 Waddell, R. D., S309
 Waecker, N. J., Jr., 356
 Wagener, M. M., 322
 Wagener, M. W., 870
 Walawander, A., 749
 Wald, A., 261
 Waldman, G., 413
 Wallace, R. J., Jr., 288
 Walsh, T. J., 662, 696
 Walters, M. I., 784
 Walters, S., 624
 Wan, P.-C. T., 241
 Wang, S. A., 35
 Wang, Z., 823
 Wasser, J., 152
 Watanakunakorn, C., 238, 572
 Watine, J., 395
 Watt, G., 819
 Watts, H., S15
 Weber, G., 319
 Weber, T., 95
 Weinberg, E. D., 991
 Weinberger, M., 240
 Weinstein, M. P., 165
 Weintraub, A., 770
 Welch, K., 407
 Wessel, V. C., 851
 Whalen, C. C., S279
 Wheat, J., 688
 Wheat, L. J., 3, 29, 141, 877
 Whelan, A. O., S283, S291
 Whimbey, E., 965
 White, D. R., 627
 White, N. J., 836
 Whitney, C., 520
 Widell, A., 585
 Wiebe, T., 585
 Wilde, H., 218
 Williams, A., S299
 Williams, B., 877
 Williams, H. V., 618
 Williams, P. L., 349, 658
 Wilson, M. E., S262
 Winstead, J. M., 87
 Winston, D. J., 236, 790
 Winter, C., 901
 Winther, B., 387
 Wise, G. J., 14
 Wong, S. S. Y., 882
 Worku, S., S257
 Wormser, G. P., 545
 Wurtz, R., 817
 Yabuta, Y., 185
 Yagupsky, P., 319
 Yang, H.-M., 823
 Yang, W.-C., 823
 Yao, J., 825
 Yebra, M., 603
 Yee, A. M. F., 25
 Yeh, S. H., 599
 Yiannoutsos, C., 749
 Yoshikawa, T. T., 931
 Yoshimura, K., 313
 Young, D. B., S254
 Young, L., 425
 Young, L. S., 235
 Young, N. S., 569
 Yu, E. I., 293
 Yu, V. L., 473, 870
 Yuen, K.-y., 882, 989
 Yutani, C., 611
 Zala, C., S143
 Zaleznik, D. F., 276
 Zangwill, K. M., 599
 Zervos, M., 19
 Zier, K., 934
 Zimmerli, W., 837
 Zumla, A., S309
 Zuniga, R., 25

Subject Index

Abacavir, for HIV infection, 313
 adverse effects, S96
 resistance to, S185

Abdominal infections
 due to *Aspergillus*, practice guidelines, 696
 due to *Staphylococcus aureus*, methicillin-resistant, in liver transplantation, 322
 treatment with quinolones, 243

Abscess
 brain
 due to *Aspergillus*, practice guidelines, 696
 due to *Salmonella typhimurium*, 621
 due to *Streptococcus intermedius*, 396
 due to *Capnocytophaga granulosa*, 606
 epidemiology, in injection drug users, 579
 liver, due to *Staphylococcus aureus*, in chronic granulomatous disease, treatment with granulocyte-macrophage colony-stimulating factor, 222

parapharyngeal, in cat-scratch disease, 599

paraspinal, due to *Peptostreptococcus micros*, 622

ABT-378, for HIV infection, S160

Acidosis, lactic, due to stavudine, 198

Acinetobacter infections
 bacteremia, antibiotic susceptibility surveillance, 454
 resistance in, 454

Acquired immunodeficiency syndrome (*see* Human immunodeficiency virus infection)

Acyclovir
 for herpes simplex virus encephalitis, 185
 prophylactic
 for lymphoma, in HIV infection, 757, 762
 for opportunistic infections, S25, S29

Adefovir, for HIV infection
 adverse effects, S96
 resistance to, S185

Adjuvants, for vaccines, S266

Aeromonas infections
 clinically relevant species, 988
 diarrhea
 in Swedish adults, 770

AG-1776, for HIV infection, S160

Aging, epidemiology, infectious disease and, 931

AIDS (*see* Human immunodeficiency virus infection)

Alatrofloxacin, state-of-the-art, 243

Albendazole, for cutaneous larva migrans, 811

Albumin, *Enterobacter cloacae* contamination of, 35

Allergic bronchopulmonary aspergillosis, practice guidelines, 696

Alternariosis, skin, 13, 174

Amikacin, extended-interval dosing, national survey, 433, 440

Aminoglycosides
 extended-interval dosing, national survey, 433, 440
 for *Mycobacterium terrae* infections, 444
 resistance to, enterococci, 799

Amniotic fluid, herpes simplex virus type 2 in, 363

Amoxicillin, for *Streptococcus pneumoniae* pneumonia [*letter and reply*], 234

Amphotericin B

for aspergillosis, 696
 for blastomycosis, 679, 969
 for candidiasis, practice guidelines, 662
 for coccidioidomycosis, 658
 for cryptococcosis, 710
 in HIV infection, 47
 practice guidelines for, 653, 662
 for histoplasmosis, 595, 688
 lipid formulations
 practice guidelines for, 653
 for invasive infections [*letter*], 236

prophylactic
 for neutropenia, 300
 for opportunistic infections, S25
 for sporotrichosis, 684
 for urinary tract infections, 14
 for zygomycosis, 851

Ampicillin, resistance to, *Shigella*, 515

Amprenavir, for HIV infection, S160, 313
 adverse effects, S96
 in drug combinations, S160
 pharmacodynamics, S151

Anaerobic bacteria, susceptibility testing, 799

Ancylostoma braziliense infections, larva migrans in, treatment, 811

Aneurysm, aortic
 due to *Chlamydia pneumoniae*, 946
 due to *Staphylococcus aureus*, in dialysis, 823

Animal models
 tuberculosis treatment, S288

tuberculosis vaccination
 domestic livestock, S222
 guinea pigs, S299
 livestock, S283, S291
 mouse, S283
 primate, S210
 wildlife, S222

Animals, opportunistic infections from, prophylaxis, S29

Anthrax, vaccination, 843

Antibiotics (*see also* specific antibiotics)
 intravenous, home program for, managed care financial impact, 639
 new treatment options, June News and Events
 prophylactic (*see* Prophylaxis)
 resistance to (*see* Drug resistance)
 shortage, February News and Events
 susceptibility testing (*see* Susceptibility testing)

Antifungal drugs (*see also* specific drugs and infections)
 practice guidelines for, 653

Antiretroviral agents, for HIV infection (*see also* highly active antiretroviral therapy; (*specific drugs*))
 adherence issues in, S96, S171
 adverse effects, S96
 combinations in, S123
 drug interaction optimization, S123
 hydroxyurea adjuvant with, S143, S193
 lipodystrophy syndrome due to, S135
 pharmacodynamics, S151
 pharmacokinetics, S123
 protease inhibitors, S160
 protease inhibitor-sparing regimens, S130
 resistance to, S117, S185
 virologic response to, S177

Aorta, mycotic aneurysm
 due to *Chlamydia pneumoniae*, 946

due to *Staphylococcus aureus* in dialysis, 823
 Aortic valve, bicuspid, endocarditis in, 336
Arthralgia
 in HIV infection, primary, in African women, 486
 in parvovirus B19 infections, 500
Arthritis
 due to *Histoplasma capsulatum*, practice guidelines, 688
 due to Lyme disease vaccine, May News and Events
 septic
 due to *Candida*, practice guidelines, 662
 due to *Clostridium*, 590
Aspergilloma, practice guidelines, 696
Aspergillosis
 fulminant, in malaria, 938, 940
 immunorestitution disease in, 882
 invasive, practice guidelines, 696
 in multiple myeloma, 41
 nosocomial [letter], 984
 practice guidelines, 696
 prophylaxis, in neutropenia, 300
 sinusitis, pneumocephalus in, 215
Asthenia, due to antiretroviral agents, S96
Astrovirus infections, diarrhea, in Swedish adults, 770
Ataxia, in tularemia, 211
Atovaquone, prophylactic, for opportunistic infections, S25, S29
Azithromycin
 for *Mycobacterium avium* complex infections, 288
 prophylactic, for opportunistic infections, S25, S29

Bacille Calmette-Guérin
 chemotherapy solution contamination with, 356
 vaccination with
 disadvantages, S233
 efficacious strain identification in, S250
 efficacy, S262
 animal models, S299
 ethical issues in, S271
 geographical effects on, S262
 historical background, S262
 mucosal, S217
 vs. *Mycobacterium bovis* infections, S291
 primate model, S210
 T lymphocyte response in, S257
 in transplantation, 857
 trial design, S206
 trials, S213
 veterinary, S222
 Back pain, in echinococcal cyst, 442, 567
Bacteremia
 antibiotic susceptibility surveillance, 454
 due to *Bacteroides*, prospective observational trial, 870
 due to *Chlamydia pneumoniae*, aortic aneurysm in, 946
 due to *Enterobacter cloacae*, nosocomial, 35
 due to *Enterococcus faecium*
 treatment with linezolid, 403
 vancomycin-resistant
 mortality in, 466
 treatment with quinupristin/dalfopristin, 790
 epidemiology, in rehabilitation unit, 425
 due to *Klebsiella pneumoniae*, ciprofloxacin-resistant, 473
 due to *Moraxella osloensis*, 179
 due to *Neisseria meningitidis*
 case reviews for 25-year period, 87
 fulminant, coagulopathy markers in, 643
 due to nontyphoid *Salmonella*, age-related differences [letter and reply], 239
nosocomial
 contaminants vs. true pathogens in [letter], 986
 ocular lesions in, 306
 in portosystemic shunt, 384
 due to *Staphylococcus aureus*
 aortic aneurysm in, 823
 database on, 633
 methicillin-resistant, pathogenic significance, 368
 due to *Stenotrophomonas maltophilia*, in bone marrow transplantation, 195
 due to *Streptococcus pneumoniae*
 Fc_{RIIIa}-R131 allotype and, 25
 penicillin-resistant, outcome, 520
 serogroups in, vaccine implications, 122
Bacteroides, vaginal colonization, variation with menstrual cycle, 901
Bacteroides infections, bacteremia, prospective observational trial, 870
Bananas, necrotizing fasciitis due to, e-mail hoax, April News and Events
Bartonella
Coxiella burnetii cross-reactivity with, 609
 detection, 166
Bartonella infections
 in HIV infection, prophylaxis, S29
 parapharyngeal abscess, 599
Behavior modification, in opportunistic infection prevention, S15
Bell's palsy, due to varicella-zoster virus, 529
Biopsy, stereotactic, brain lesions, in HIV infection, 491
Bioterrorism
 challenges, 926
 vaccination for, May News and Events, 843
Bismuth therapy, for *Helicobacter pylori* infections, serologic evaluation after, 976
Blastocystis hominis infections, diarrhea, in Swedish adults, 770
Blastomycosis
 central nervous system, recurrent, 969
 epidemiology, 582
 molecular epidemiology, 328
 practice guidelines, 679
Blood cells, suppression, in HIV infection, 504
BMS-232632, for HIV infection, S160
Bone infections (see *Osteomyelitis*)
Bone marrow
 dysfunction, in HIV infection, 256
 suppression, due to antiretroviral agents, S96
 transplantation, *Stenotrophomonas maltophilia* bacteremia in, 195
Book reviews
AIDS Therapy, 815
Clinical Infectious Diseases: A Practical Approach, 816
Current Clinical Topics in Infectious Diseases, 817
Cytotoxic Lymphocytes: Basic Mechanisms and Medical Applications, 934
Infectious Diseases, 818
Management of Respiratory Tract Infections, 935
Tropical Infectious Diseases: Principles, Pathogens, and Practice, 816
Bordetella, detection, 166
Bordetella bronchiseptica infections, with cytomegalovirus infections, in malnutrition [letter], 408
Bordetella infections (see also *Pertussis*)
 cough in, 387
Borrelia burgdorferi, detection, 166

Borreliosis (*see* Lyme disease)
 Botulism, vaccination, 843
 Brain
 abscess
 due to *Aspergillus*, practice guidelines, 696
 due to *Salmonella typhimurium*, 621
 due to *Streptococcus intermedius*, 396
 borreliosis, treatment [letter], 237, 410
Coccidioides immitis hyphal forms in, 349
 encephalitis (*see* Encephalitis)
 increased intracranial pressure on, in meningitis, due to *Cryptococcus neoformans*, 47
 inflammation of (*see* Encephalitis)
 lesions, in HIV infection, stereotactic biopsy, 491
 meningeal inflammation (*see* Meningitis)
 metronidazole effects on, 211
 rabies virus infections, 4
 tuberculoma, treatment, 625
 tularemia effects on, 211
 Brain-stem, encephalitis, due to herpes simplex virus, herpes zoster oticus with, 229
 Bronchiectasis, in voluntary cough suppression, 572
 Bronchitis
 due to *Aspergillus*
 in malaria, 938
 practice guidelines, 696
 treatment, with quinolones, 243
Brucella infections
 organism detection in, 166
 vaccination, 843
Burkholderia pseudomallei infections, treatment [letter], 235
 Butoconazole, for candidiasis, practice guidelines, 662
 Calcium carbonate, for diarrhea, protease inhibitor-associated, 908
 Calicivirus infections, diarrhea, in Swedish adults, 770
Campylobacter infections, diarrhea
 in Swedish adults, 770
 Cancer
 funguria in, 14
 hepatitis C in, treatment, in pediatric patients, 585
 immunorestitution disease in, 882
 Mycobacterium kansasii infections in, 965
 zygomycosis in, 851
 Candidemia, practice guidelines, 662
 Candidiasis
 disseminated, practice guidelines, 662
 hepatosplenic, immunorestitution disease in, 882
 in HIV infection
 primary, in African women, 486
 prophylaxis, S29
 refractive, 749
 prophylaxis, in neutropenia, 300
 treatment
 in HIV infection, failure, 749
 practice guidelines, 662
 urinary, in hospitalized patients, 14
 Candiduria, treatment, with fluconazole, 19
Capnocytophaga granulosa infections, abscess, 606
 Carriage (*see* Colonization)
 Catheter-related infections
 urinary, due to fungi, 14
 vascular
 in HIV infection, 949
 due to methicillin-resistant *Staphylococcus aureus*, 322
 due to *Methylobacterium mesophilicum*, 936
 Cats
 cat-scratch disease due to, parapharyngeal abscess in, 599
 plague associated with, 893
 Cefotaxime, resistance to, *Streptococcus pneumoniae*, 71
 Ceftriaxone
 for neurosyphilis, in HIV infection, 540
 for *Staphylococcus aureus* osteomyelitis, 205
 Cellulitis, epidemiology, in injection drug users, 579
 Centers for Disease Control and Prevention, budgeting practices, April News and Events
 Central nervous system infections (*see also* Brain)
 due to *Aspergillus*, practice guidelines, 696
 due to *Blastomyces dermatitidis*, recurrent, 969
 due to *Coccidioides immitis*, hyphal forms in, 349
 due to *Cryptococcus neoformans*, practice guidelines, 710
 due to *Histoplasma capsulatum*, 595, 688
 due to *Pneumocystis carinii*, in HIV infection, treatment, 397
 Cephalosporins, for *Neisseria meningitidis* pneumonia, case reviews for 25-year period, 87
 Cerebellar ataxia, in tularemia, 211
 Cerebrospinal fluid
 Coccidioides immitis hyphal forms in, 349
 herpes simplex virus detection in, 176
 HIV load in, vs. neurologic symptoms, 962
 Mycoplasma pneumoniae detection in [letter and reply], 405
 Chemotherapy
 aspergillosis in, 41
 for leukemia, hepatic granuloma after, due to *Propionibacterium acnes*, 219
 Mycobacterium bovis infections in, from contaminated solutions, 356
 Chickenpox (*see* Varicella-zoster virus infections)
 Chlamydial infections, treatment, with quinolones, 243
Chlamydia pneumoniae infections
 aortic aneurysms in, 946
 cough in, 387
 meningoencephalitis, 209
Chlamydia trachomatis infections
 in military, 736, 742
 screening for, with polymerase chain reaction [letter and reply], 406
 Chloramphenicol
 in pregnancy [letter], 237
 resistance to, *Shigella*, 515
 Cholesterol, elevation, due to antiretroviral agents, S96
 Chorioretinitis, due to *Treponema pallidum*, 479
 Chronic granulomatous disease, liver abscess in, treatment with granulocyte-macrophage colony-stimulating factor, 222
 Cidofovir
 for cytomegalovirus retinitis, in HIV infection, 182
 for progressive multifocal leukoencephalopathy [letter], 234
 prophylactic, for opportunistic infections, S25
 Ciprofloxacin
 prophylactic, for opportunistic infections, S29
 resistance to, *Klebsiella pneumoniae*, 473
 state-of-the-art, 243
 Cirrhosis, liver, necrotizing fasciitis in, due to *Klebsiella pneumoniae* [letter], 989
 Clarithromycin
 for *Mycobacterium avium* complex infections, 288
 prophylactic, for opportunistic infections, S25, S29

Clostridium difficile, colonization, in hospital ward, 952
Clostridium difficile infections
 diarrhea
 in rehabilitation unit, 425
 in Swedish adults, 770
 necrotizing fasciitis, 954
Clostridium infections, septic arthritis, 590
Clotrimazole, for candidiasis, practice guidelines, 662
Coagulopathy, in *Neisseria meningitidis* infections, markers for, 643
Coccidioidomycosis
 central nervous system, hyphal forms in, 349
 in HIV infection, prophylaxis, S29
 outbreak, 61
 peritonitis, 971
 practice guidelines, 658
 skin testing for, in California, 612
Cognitive dysfunction, due to antiretroviral agents, S96
Colonization
Clostridium difficile, in hospital ward, 952
 epidemiology, in rehabilitation unit, 425
Giardia lamblia, in infants, 419
Klebsiella pneumoniae, drug-resistant, 55
Streptococcus pneumoniae, penicillin-resistant, 191
 vaginal, variation with menstrual cycle, 901
Common cold, nasal fluid flow and pressures in, during blowing, sneezing, and coughing, 387
Computed tomography, of nasal fluid flow, during blowing, sneezing, and coughing, 387
Conjunctivitis, in West Nile virus infections, 413
Coronary artery bypass graft surgery, radial artery harvest site infections in, risk factors for, 270
Cotton-wool spots, in bacteremia, 306
Cough
 nasal fluid flow and pressures in, 387
 nonproductive, in military force population, causes, 534
 suppression, in *Mycobacterium avium* complex infections, 572
 in tuberculosis, population-based survey, 293
Coxiella burnetii infections
 outbreaks, 214
 vaccination, 843
Crohn's disease, treatment with metronidazole, psychiatric symptoms due to, 213
Cryptococcosis
 in HIV infection
 meningitis, 47
 prophylaxis, S29
 treatment of, 710
 immunorestitution disease in, 882
 practice guidelines, 710
Cryptosporidiosis
 diarrhea
 in Swedish adults, 770
 in HIV infection, prophylaxis, S29
Culture
Bartonella, 166
Bordetella, 166
Borrelia burgdorferi, 166
Brucella, 166
 fastidious bacteria, 166
Francisella tularensis, 166
Legionella, 166
Leptospira, 166
Cutaneous larva migrans, treatment, 811
Cutaneous leishmaniasis, epidemiology, East Timor [letter], 840
Cyst(s), echinococcal, of spine, 442, 567
Cystocele, recurrent infections in, 152
Cytokines, as vaccine adjuvants, S266
Cytomegalovirus infections
 in HIV infection
 prophylaxis, S1, S15
 retinitis, 182, 231
 immunorestitution disease in, 882
 in malnutrition, with *Bordetella bronchiseptica* infections [letter], 408
 vaccination, in transplantation, 857
Cytoplasmic retinoic acid binding protein, inhibition, antiretroviral agents in, S135
Cytosine arabinoside, for progressive multifocal leukoencephalopathy [letter], 234
Dapsone, prophylactic, for opportunistic infections, S25, S29
Delavirdine, for HIV infection
 adverse effects, S96
 in drug combinations, S123, S130
 resistance to, S185
Dengue fever
 in HIV infection, HIV antibody testing in, 819
 outbreaks, March New and Events
Diabetes mellitus
 due to antiretroviral agents, S96, S135
funguria in, 14
 necrotizing fasciitis in, due to *Klebsiella pneumoniae* [letter], 989
 radial artery harvest site infections in, 270
Dialysis, aortic aneurysm in, due to *Staphylococcus aureus*, in dialysis, 823
Diarrhea
 due to antiretroviral agents, S96
 due to *Clostridium difficile*, in rehabilitation unit, 425
 enteropathogen identification in, in Swedish adults, 770
 in HIV infection, primary, in African women, 486
 due to protease inhibitors, in HIV infection, 908
 due to protozoa, reporting practice guidelines for, 401
 requiring hospitalization, organisms causing, in pediatric patients, 953
Didanosine, for HIV infection
 adverse effects, S96
 in drug combinations, S123, S130, S143
 hydroxyurea with, S193
 resistance to, S185
Dideoxycytidine, for HIV infection, resistance to, S185
Diphenoxylateatropine, for diarrhea, protease inhibitor-associated, 908
Diphtheria, vaccination, in transplantation, 857
Diskitis, due to *Peptostreptococcus micros*, 622
DNA vaccines, tuberculosis, S233, S283
 animal models, S283
 regulatory process for, S247
Doxycycline, for neuroborreliosis [letter], 237, 410
Drug abuse, injection
 abscess prevalence in, 579
 cellulitis prevalence in, 579
 endocarditis in, pathogenesis, 374
 opportunistic infection prophylaxis in, S29
Drug resistance (see also Susceptibility testing)
Acinetobacter, 454
ampicillin, *Shigella*, 515

Bacteroides, 870
 cefotaxime, *Streptococcus pneumoniae*, 71
 chloramphenicol, *Shigella*, 515
 ciprofloxacin, *Klebsiella pneumoniae*, 473
 enterococci
 aminoglycosides, 799
 vancomycin (see Enterococcal infections, vancomycin-resistant)
 epidemiology, in rehabilitation unit, 425
 gram-positive organisms, linezolid for, 146
 human immunodeficiency virus, S177
 test methods for, S117
Klebsiella pneumoniae, 55
 ciprofloxacin, 473
 mechanisms, difficult-to-detect, 799
 methicillin, *Staphylococcus aureus* (see *Staphylococcus aureus* infections, methicillin-resistant)
 multiple
 HIV, S185
Klebsiella pneumoniae, 55
 linezolid for, 146
Mycobacterium tuberculosis, 617
Shigella, 515
Neisseria meningitidis, in 1997, 212
 penicillin, *Streptococcus pneumoniae*, 78, 191, 454, 520
Pseudomonas aeruginosa, 454
 quinolones, 243, 454
 SENTRY surveillance program, 454
Shigella, 515
Staphylococcus aureus
 methicillin (see *Staphylococcus aureus* infections, methicillin-resistant)
 vancomycin, 799
Streptococcus pneumoniae
 cefotaxime, 71
 penicillin, 78, 191, 520
 surveillance for, 454
 streptomycin, *Shigella*, 515
 sulfisoxazole, *Shigella*, 515
 tetracycline, *Shigella*, 515
 trimethoprim-sulfamethoxazole, *Shigella*, 515
 vancomycin
 enterococci (see Enterococcal infections, vancomycin-resistant)
Staphylococcus aureus, 799
 Duke criteria, for endocarditis diagnosis, proposed modifications, 633
 Dyslipidemia, due to antiretroviral agents, S96
 Dyspepsia, due to antiretroviral agents, S96
 Ear infections
 due to *Aspergillus*, practice guidelines, 696
 due to *Mycobacterium tuberculosis*, treatment, paradoxical reaction in, 625
 Echinococcal cyst, spinal, 442, 567
 Echocardiography, in endocarditis, accuracy of, 825
 Economic issues
 Centers for Disease Control and Prevention budgeting practices, April News and Events
 in home intravenous antibiotic program, 639
 Editorial, 1
 Education
 on HIV transmission prevention, in military, 730
 on opportunistic infections in HIV infection, S15
 on raw meat irradiation, March News and Events
 on *Streptococcus pneumoniae* vaccination, April News and Events

Efavirenz, for HIV infection, 313
 adverse effects, S96
 in drug combinations, S123
 hypersensitivity to, 227
 resistance to, S185
 Elderly persons, infectious disease in, 931
 ELISA (enzyme-linked immunosorbent assay), for Lyme disease, 545
 E-mail hoax, on bananas and necrotizing fasciitis, April News and Events

Encephalitis
 due to *Chlamydia pneumoniae*, 209
 due to herpes simplex virus
 herpes zoster oticus with, 229
 treatment, 185
 vaccination, 549
 tick-borne, isolated initial phase [letter], 987
 due to Togavirus, 188
 due to *Toxoplasma gondii*, in HIV infection, prophylaxis, S15, 602

Venezuelan equine, vaccination, 843
 due to Venezuelan equine encephalitis complex, 188
 due to West Nile virus, 413

Endocarditis
 due to *Aspergillus*, practice guidelines, 696
 in bicuspid aortic valve, 336
 due to *Candida*, practice guidelines, 662
 due to *Coxiella burnetii*, *Bartonella* cross-reactivity in, 609
 diagnosis, Duke criteria for, proposed modifications, 633
 echocardiography in, accuracy of, 825
 due to *Francisella tularensis*, 399
 due to β -hemolytic streptococci, mortality in, 624
 due to *Mycobacterium fortuitum*, 605, 629
 due to *Propionibacterium acnes*, in liver transplantation, 224
 right-side, in injection drug users, pathogenesis, 374
 due to *Sakessaea vasiformis*, 942
 Endophthalmitis, due to *Candida*, practice guidelines, 662
Entamoeba infections, in HIV infection, epidemiology, 955, 959
Enterobacter cloacae infections, bacteremia, nosocomial, 35
Enterobacteriaceae, susceptibility testing, 799
 Enterococcal infections
 resistance in, aminoglycosides, 799
 vancomycin-resistant, 403
 bacteremia, mortality in, 466
 surveillance for, 454
 susceptibility testing, 799
 treatment
 with linezolid, 146
 with quinupristin/dalfopristin, 790
Enterococcus faecalis infections, bacteremia, after portosystemic shunt placement, 384
Enterococcus faecium infections
 bacteremia, antibiotic susceptibility surveillance, 454
 vancomycin-resistant
 bacteremia, treatment with linezolid, 403
 mortality in, 466
 treatment, with quinupristin/dalfopristin, 790
 Enterotoxin, staphylococcal, vaccination, 843
 Enterovirus 71 infections, treatment [letter], 988
 Environmental exposures, to opportunistic infections, prophylaxis, S29
 Epidemics, tuberculosis, control with vaccines, S316
 Epidemiology (see also Outbreaks)
 abscesses, in injection drug users, 579
 aging, infectious disease and, 931

blastomycosis, 582
 organism diversity, 328

cellulitis, in injection drug users, 579

Chlamydia trachomatis infections, in military, 736, 742

Clostridium difficile, in hospital ward, 952

Coccidioides immitis infections, in returned travelers, 61

Coccidioides immitis-positive skin tests, in California, 612

dengue fever, March New and Events

Entamoeba infections, in HIV infection, 955, 959

GB virus C/hepatitis G virus infections, in pediatric patients, 569

group B streptococcal infections in, maternal and neonatal, 276

helminth infections, in HIV infection [letter], 241

influenza

March New and Events

Klebsiella pneumoniae infections, multidrug-resistant, 55

Neisseria gonorrhoeae infections, in military, 736, 742

nosocomial infections in rehabilitation unit, 425

sporotrichosis, Peru, 65

Streptococcus pneumoniae
 serogroups for vaccines, 100, 122
 serotype 1, 319

tuberculosis, S233

West Nile virus infections, 413

Epstein-Barr virus, detection in lymphoma, after kidney transplantation, 576

Epstein-Barr virus infections
 prophylaxis, in HIV infection, 757, 762
 vaccination, in transplantation, 857

Equine encephalitis complex, Venezuelan, tonate virus subtype of, 188

Errata
 cat-scratch disease (2000;30:599), 841
 influenza vaccination (2000;30:342), 992
Neisseria vaccine (1999;29:1295), 632
 rifabutin use with protease inhibitors (2000;30:779), 992
 West Nile virus outbreak (2000;30:413), 841

Erythromycin, for pertussis, February News and Events

ESAT-6 antigen, *Mycobacterium tuberculosis*, T lymphocyte recognition, S201

Escherichia coli infections
 bacteremia, antibiotic susceptibility surveillance, 454
 enteroaggregative, diarrhea, in Swedish adults, 770
 enterotoxigenic, diarrhea
 in Swedish adults, 770
 hemolytic-uremic syndrome in [letter and reply], 984
 in rehabilitation unit, 425
 urinary tract, Shiga toxin-producing, hemolytic-uremic syndrome in, 395

Esophageal infections, due to *Candida*, practice guidelines, 662

Ethambutol
 for *Mycobacterium avium* complex infections, 288
 for *Mycobacterium terrae* infections, 444
 prophylactic, for opportunistic infections, S25

Ethical issues, in tuberculosis vaccine trials, S271

Exophiala jeanselmei infections, prophylaxis, in neutropenia, 300

Eye disorders, in bacteremia, 306

Eye infections
 due to *Aspergillus*, practice guidelines, 696
 due to *Candida*, practice guidelines, 662
 due to herpes simplex virus, 549
 due to *Treponema pallidum*, 479

Facial nerve
 herpes zoster, with herpes simplex virus encephalitis, 229
 palsy, due to varicella-zoster virus, 529

Faecal bacteria, susceptibility testing, 799

Famciclovir, prophylactic, for opportunistic infections, S29

Fasciitis, necrotizing (see Necrotizing fasciitis)

Fat, maldistribution, due to antiretroviral agents, S96, S135

Fat graft, necrosis, lipoid meningitis in, 613

Fatigue, due to antiretroviral agents, S96

Fc_{RIIIa}-R131 allotypes, in *Streptococcus pneumoniae* pneumonia severity, 25

Fever
 in critical illness, evaluation [letter], 234

dengue
 in HIV infection, HIV antibody testing in, 819
 outbreaks, March New and Events

in histoplasmosis, 595

in HIV infection, primary, in African women, 486

in neutropenia, treatment, with quinolones, 243

Q
 endocarditis in, *Bartonella* cross-reactivity in, 609
 outbreaks, 214
 vaccination, 843

rabbit (see Tularemia)

in tuberculosis, population-based survey, 293

in West Nile virus infections, 413

Filgrastim, in neutropenia, in HIV infection, 256

Fluconazole
 for blastomycosis, 679
 for candidiasis
 in HIV infection, failure, 749
 practice guidelines, 662

for candiduria, 19

for coccidioidomycosis, 658, 971

for cryptococcosis, 710

practice guidelines for, 653

for histoplasmosis, 688

prophylactic, for opportunistic infections, S25, S29

for sporotrichosis, 684

for urinary tract infections, 14

Flucytosine
 for candidiasis, practice guidelines, 662
 for cryptococcosis, 710
 practice guidelines for, 653
 for meningitis, due to *Cryptococcus neoformans*, in HIV infection, 47

Fluoroquinolones, state-of-the-art, 243

Food, antiretroviral agent interactions with, S96

Foodborne diseases
 in HIV infection, prophylaxis, S29
 raw meat irradiation and, patient education on, March News and Events

Foscarnet, prophylactic
 for lymphoma, in HIV infection, 757, 762
 for opportunistic infections, S25, S72

Francisella tularensis, detection, 166

Francisella tularensis infections
 ataxia in, 211
 endocarditis, 399
 vaccination, 843

Fungal infections (see also specific fungi)
 in HIV infection, prophylaxis, S1, S15
 practice guidelines for (see under Infectious Diseases Society of America, practice guidelines)

prophylaxis, in neutropenia, 300

Funguria, surveillance, 14

Gallbladder infections, due to *Candida*, practice guidelines, 662

Ganciclovir, prophylactic

- for lymphoma, in HIV infection, 757, 762
- for opportunistic infections, S25, S29, S72

Gangrene, due to *Clostridium difficile*, 954

Gastrointestinal infections (see also Diarrhea)

- in HIV infection, prophylaxis, S29
- inflammatory pseudotumor formation in, in HIV infection, 826
- due to *Mycobacterium avium* complex, in heart transplantation, 603

GB virus C/hepatitis G virus infections, epidemiology, in pediatric patients, 569

Gemella morbillorum infections, bacteremia, after portosystemic shunt placement, 384

Genital infections

- due to *Candida*, practice guidelines, 662
- due to herpes simplex virus

 - amniotic fluid viral load in, 363
 - vaccination, 549
 - viral shedding in, 261, 268
 - susceptibility to, menstrual cycle and, 901

Gentamicin

- extended-interval dosing, national survey, 433, 440
- for *Francisella tularensis* endocarditis, 399

Giardia intestinalis infections, diarrhea, in Swedish adults, 770

Giardia lamblia, carriage, in infants, 419

Gingivostomatitis, due to herpes simplex virus, vaccination, 549

Glucose intolerance, due to antiretroviral agents, S96

Gonorrhea (see *Neisseria gonorrhoeae* infections)

Gram-positive infections, resistance in, treatment with linezolid, 146

Granulocyte colony-stimulating factor, in neutropenia, in HIV infection, 256

Granulocyte-macrophage colony-stimulating factor

- with influenza vaccination, in stem-cell transplantation, 342
- for liver abscess, due to *Staphylococcus aureus*, in chronic granulomatous disease, 222

Granuloma, hepatic, due to *Propionibacterium acnes*, 219

Granulomatous disease, due to *Leishmania donovani*, 764

Grepafloxacin, state-of-the-art, 243

Growth, *Giardia lamblia* colonization effects on, 419

HAART (see Highly active antiretroviral therapy)

Haemophilus, susceptibility testing, 799

Haemophilus aphrophilus infections, lymphadenitis in, 627

Haemophilus influenzae infections

- pneumonia, in HIV infection, 461
- vaccination

 - in transplantation, 857
 - trial design, S206

Handwashing, vs. hand disinfection [letter], 990

Headache

- due to antiretroviral agents, S96
- in HIV infection, primary, in African women, 486
- in West Nile virus infections, 413

Heart

- endocarditis (see Endocarditis)
- transplantation, *Mycobacterium avium* complex intestinal infections in, 603
- valvular disease, endocarditis in, 336

Helicobacter pylori infections, treatment, serologic evaluation, 976

Helminth infections, in HIV infection, epidemiology [letter], 241

Hemolytic-uremic syndrome

- due to *Escherichia coli* [letter and reply], 984

in *Escherichia coli* infections, Shiga toxin-producing, 395

Hemoptysis, in tuberculosis, population-based survey, 293

Hepatitis, due to trovafloxacin, 400

Hepatitis A

- in HIV infection, prophylaxis, S15, S29
- vaccination, in transplantation, 857

Hepatitis B

- in HIV infection, prophylaxis, S15, S29
- immunorestitution disease in, 882
- vaccination, in transplantation, 857

Hepatitis C

- in health care workers, May News and Events
- in HIV infection, S77
- prophylaxis, S1, S29
- survival effects [letter and reply], 409
- treatment, in pediatric patients, 585

Hepatitis E, in California, 618

Hepatitis G, epidemiology, in pediatric patients, 569

Hepatosplenic candidiasis, practice guidelines, 662

Herpes simplex virus infections

- encephalitis

 - herpes zoster oticus with, 229
 - treatment, exacerbation after, 185

- in HIV infection, prophylaxis, S1, S29
- meningitis, immunogenetic determinants, 176
- peritonitis [letter], 839
- type 2

 - amniotic fluid viral load in, 363
 - viral shedding in, in homosexual men, 261, 268

- urethritis, screening for, 982
- vaccination

 - review article, 549
 - in transplantation, 857

Herpes zoster, facial palsy in, 529

Herpes zoster oticus, with herpes simplex virus encephalitis, 229

Highly active antiretroviral therapy, for HIV infection

- adherence to, S96, S171
- adverse effects, S96
- immunorestitution disease in, 882
- incomplete response to [letter], 407
- with JC virus infection, 95
- Mycobacterium avium* complex infection recurrence after, 511
- opportunistic infection prevention in (see Opportunistic infections, in HIV infection, prevention)
- resistance to, S185
- toxoplasmosis prophylaxis discontinuation in, 602
- in tuberculosis, 779

Histoplasmosis

- in HIV infection
- prophylaxis, S29
- severe, 877
- practice guidelines, 688
- prostate involvement in, 595

HIV infection (see Human immunodeficiency virus infection)

Hodgkin's disease, immunorestitution disease in, 882

Home-care programs, for intravenous antibiotics, managed care financial impact, 639

Homosexual persons, herpes simplex virus type 2 shedding in, 261, 268

Hookworm disease, larva migrans in, treatment, 811

Human herpesvirus 8 infections, in HIV infection, S72

- prophylaxis, S1
- without Kaposi's sarcoma development, 221

Human immunodeficiency virus, mutation, S185
 Human immunodeficiency virus infection
Bartonella infections in, prophylaxis, S29
 brain lesions in, stereotactic biopsy, 491
 candidiasis in
 prophylaxis, S29
 refractive, 749
 catheter infections in, 949
 central nervous system infections in, due to *Pneumocystis carinii*, treatment, 397
 coccidioidomycosis in, prophylaxis, S29
 cryptococcosis in
 meningitis, 47
 prophylaxis, S29
 treatment of, 710
 cryptosporidiosis in, prophylaxis, S29
 cytomegalovirus infections in
 prophylaxis, S1, S15, S29
 retinitis
 natural history, 231
 treatment, 182
 dengue fever in, HIV antibody testing in, 819
 diagnosis, early, S15
 encephalitis in, due to *Toxoplasma gondii*, prophylaxis, 602
Entamoeba infections in, epidemiology, 955, 959
 foodborne diseases in, prophylaxis, S29
 fungal infections in, prophylaxis, S1, S15
 gastrointestinal infections in, prophylaxis, S29
Haemophilus influenzae pneumonia in, 461
 helminth infections in, epidemiology [letter], 241
 hepatitis A in, prophylaxis, S15, S29
 hepatitis B in, prophylaxis, S15, S29
 hepatitis C in, S77
 prophylaxis, S1, S29
 survival effects [letter and reply], 409
 herpes simplex virus infections in, prophylaxis, S1, S29
 histoplasmosis in
 practice guidelines, 688
 prophylaxis, S29
 severe, 877
 human herpesvirus 8 infections in, S72
 prophylaxis, S1
 human herpesvirus 8 seropositivity in, without Kaposi's sarcoma
 development, 221
 human papillomavirus infections in, prophylaxis, S29
 immunorestitution disease in, 882
 inflammatory pseudotumor in, resembling lymphoma, 826
 influenza in, prophylaxis, S15, S29
 JC virus infections in, treatment, 95
 Kaposi's sarcoma in, S72
 prophylaxis, S1
 lymphoepithelial parotid lesions in, malignant transformation, 947
 lymphoma in, 491, 947
 prevention with acyclovir, 757, 762
 malaria in, HIV antibody testing in, 819
 meningitis in, due to *Cryptococcus neoformans*, 47
Mycobacterium avium complex infections in
 prophylaxis, S1, S15, S29, S66
 recurrence after therapy, 511
Mycobacterium terrae infections in, 831
 neurologic disorders in, vs. cerebrospinal fluid viral load, 962
 neurosyphilis in, treatment, 540
 neutropenia in, 256

opportunistic infections in (see Opportunistic infections, in HIV infection; specific infections)
Pneumocystis carinii infections in
 central nervous system, treatment, 397
 pneumonia, diagnosis, 141
 prophylaxis, S1, S15, S29, S66
 pneumonia in
 due to *Haemophilus influenzae*, 461
 due to *Pneumocystis carinii*, diagnosis, 141
 in pregnancy, opportunistic infection prophylaxis in, S15
 primary
 clinical features, in African women, 486
 neurologic disorders in, vs. cerebrospinal fluid viral load, 962
 resistance in, S177
 test methods for, S117
 respiratory infections in, prophylaxis, S1, S15, S29
 retinitis in, due to cytomegalovirus
 natural history, 231
 treatment, 182
Salmonella infections in, prophylaxis, S29
 sexually transmitted diseases in, prophylaxis, S29
 splenomegaly in, 943
 sporotrichosis in, practice guidelines, 684
Streptococcus pneumoniae infections in, prophylaxis, S15, S29
 syphilis in, treatment, 540
 testing for
 in dengue infections, 819
 in malaria, 819
 T lymphocytes in
 hydroxyurea effects on, S193
 opportunistic infection prevention based on, S15
 opportunistic infection prophylaxis discontinuation and, S66
 treatment response and, S177, 504
 vs. viral load, during antiretroviral therapy, 392
 toxoplasmosis in
 encephalitis, prophylaxis, 602
 prophylaxis, S29
 transmission
 prevention, in military, 730
 risk behavior for, in military, 723, 730
 travelers' diseases in, prophylaxis, S29
 treatment
 with antiretroviral agents (see Antiretroviral agents, for HIV infection; Highly active antiretroviral therapy; specific drugs)
 with combination therapy, 313
 failure, S177
 combination therapy for, 313
 hematosuppression reversal in, 504
 incomplete response to [letter], 407
 JC virus infections with, 95
 low-level viral replication during, 392
 protease inhibitor-associated diarrhea in, 908
 salvage, S160, S177
 T lymphocyte response in, S177, 504
 tuberculosis in
 prophylaxis, S1, S15, S29
 treatment with rifabutin, 779
 vaccines for, S247, S309
 vaccination in
 for opportunistic infections, S29
 rabies, 218
 with transplantation, 857

varicella-zoster infections in, prophylaxis, S1, S29
 viral load in
 vs. neurologic status, 962
 vs. T lymphocyte count, during antiretroviral therapy, 392
 treatment strategy and, S177
 waterborne diseases in, prophylaxis, S29

Human papillomavirus infections, in HIV infection, prophylaxis, S29

Hydatid cyst, of spine, 442, 567

Hydroxyurea, for HIV infection, S143, S193
 adverse effects, S96
 in drug combinations, S123

Hypercholesterolemia, due to antiretroviral agents, S96

Hyperglycemia, due to antiretroviral agents, S96, S135

Hyperlipidemia, due to antiretroviral agents, S135

Hypersensitivity reaction
 to antiretroviral agents, S96
 to efavirenz, 227
 purified protein derivative, mucosal tuberculosis vaccination effects on, S217

Hypertension, indinavir-induced, 619

Hyperthermia, malignant, in critical illness, evaluation [letter], 234

Hypertriglyceridemia, due to antiretroviral agents, S96

Immunization (see *Vaccines and vaccination*)

Immunoblot assay, for Lyme disease, 545

Immunodeficiency (see also *Chemotherapy*; *Human immunodeficiency virus infection*; *Neutropenia*; *Transplantation*)
 bacille Calmette-Guérin vaccination in, ethical issues, S271
 Blastomyces dermatitidis infections in, practice guidelines, 679
 in chronic granulomatous disease, liver abscess in, treatment with granulocyte-macrophage colony-stimulating factor, 222
 in HIV infection, reversal by treatment, 504
 immunorestitution disease in, 882

Immunorestitution disease, immune response in, 882

Incontinence, urinary, recurrent infections in, 152

Indinavir, for HIV infection, S160
 adverse effects, S96, S135
 in drug combinations, S123, S160
 pharmacodynamics, S151
 side effects, 619

Infants (see *Pediatric patients*)

Infection control, hand disinfection in [letter], 990

Infectious Diseases Society of America
 opportunistic infection prevention practice guidelines (see *Opportunistic infections, in HIV infection, prevention*)
 practice guidelines, fungal infection treatment, 652
 due to *Aspergillus*, 696
 due to *Blastomyces dermatitidis*, 679
 due to *Candida*, 662
 due to *Coccidioides immitis*, 658
 due to *Cryptococcus neoformans*, 710
 drugs for, 653
 due to *Histoplasma capsulatum*, 688
 due to *Sporothrix schenckii*, 684

Inflammatory bowel disease, treatment with metronidazole, psychiatric symptoms due to, 213

Influenza
 epidemiology, March News and Events
 in HIV infection, prophylaxis, S15, S29
 prophylaxis, zanamivir for, 587
 Streptococcus pneumoniae pneumonia and, 784
 vaccination
 in stem-cell transplantation, granulocyte-macrophage colony-stimulating factor with, 342

 in transplantation, 857

Insulin resistance, due to antiretroviral agents, S135

Interferon- α
 for enterovirus 71 infections [letter], 988
 for hepatitis C
 in HIV infection, S77
 in pediatric patients, 585

Interferon- γ , response
 to mucosal bacille Calmette-Guérin vaccination, S217
 to *Mycobacterium tuberculosis* ESAT-6 antigen exposure, S201

Interleukin-6, measurement, in fulminant *Neisseria meningitidis* infections, 643

Intracranial pressure, increased, in meningitis, due to *Cryptococcus neoformans*, 47

Irradiation, of raw meat, patient education on, March News and Events

Isoniazid
 prophylactic, for tuberculosis, S25, S29
 with rifalizil, for tuberculosis, animal model, S288

Itraconazole
 for aspergillosis, 696
 for blastomycosis, 679
 for candidiasis, practice guidelines, 662
 for coccidioidomycosis, 658
 for cryptococcosis, 710
 practice guidelines for, 653
 for histoplasmosis, 688
 prophylactic
 for neutropenia, 300
 for opportunistic infections, S25, S29
 for sporotrichosis, 684

Ivermectin, for cutaneous larva migrans, 811

JC virus infections
 in HIV infection
 brain biopsy in, 491
 treatment, 95
 treatment [letter], 234

Joint infections
 due to *Candida*, practice guidelines, 662
 due to *Clostridium*, 590
 due to *Sporothrix schenckii*, practice guidelines, 684

Kallikrein-kinin system activation, in streptococcal toxic shock syndrome, 961

Kaposi's sarcoma
 failure to develop, in human herpesvirus 8 seropositivity, 221
 in HIV infection, S72
 prophylaxis, S1

Keratitis, due to herpes simplex virus, vaccination, 549

Ketoconazole
 for blastomycosis, 679
 for candidiasis, practice guidelines, 662
 for coccidioidomycosis, 658
 practice guidelines for, 653
 for histoplasmosis, 688
 for sporotrichosis, 684

Kidney
 atrophy, indinavir-induced, 619
 failure, in histoplasmosis, 595
 stones, due to antiretroviral agents, S96
 transplantation, lymphoma after, Epstein-Barr virus detection in, 576

Klebsiella pneumoniae infections

bacteremia
 antibiotic susceptibility surveillance, 454
 ciprofloxacin-resistant, 473
 necrotizing fasciitis [letter], 989
 resistance in, 55, 473
 susceptibility testing, 799
KRM-1648 (rifalizil), for tuberculosis, animal model, S288

β -Lactamases
 detection, 799
Klebsiella pneumoniae, 473
 Lactic acidosis, due to stavudine, 198
Lactobacillus, vaginal colonization, variation with menstrual cycle, 901
Lactobacillus acidophilus infections, bacteremia, after portosystemic shunt placement, 384
 Lady Windermere syndrome, in *Mycobacterium avium* complex infections, 572
 Lamivudine, for HIV infection
 adverse effects, S96
 in drug combinations, S123, S130, S143, S160
 hydroxyurea with, S193
 resistance to, S185
 Larva migrans, cutaneous, treatment, 811
 Laryngeal infections
 due to *Aspergillus*, practice guidelines, 696
 due to *Candida*, practice guidelines, 662
Legionella, detection, 166
Legionella dumoffii infections, pneumonia, organism detection in, 382
Leishmania chagasi infections, natural history, in Brazil, 608
 Leishmaniasis
 cutaneous, epidemiology, East Timor [letter], 840
 mediastinal, 764
Leptospira, detection, 166
 Leukemia
 hepatic granuloma in, due to *Propionibacterium acnes*, 219
 hepatitis C in, treatment, in pediatric patients, 585
 immunorestitution disease in, 882
 zygomycosis in, 851
 Leukoencephalopathy, progressive multifocal in HIV infection
 brain biopsy in, 491
 treatment, 95
 treatment [letter], 234
 Levofloxacin
 for *Rhodococcus equi* meningitis, 223
 state-of-the-art, 243
 Linezolid
 for *Enterococcus faecium* infections, vancomycin-resistant, 403
 for multidrug-resistant infections, 146
 Lipodystrophy syndrome, due to antiretroviral agents, S135
 Lipoid meningitis, after autologous fat graft necrosis, 613
 Liver
 abscess, due to *Staphylococcus aureus*, in chronic granulomatous disease, treatment with granulocyte-macrophage colony-stimulating factor, 222
 cirrhosis, necrotizing fasciitis in, due to *Klebsiella pneumoniae* [letter], 989
 enzyme profiles, in antiretroviral therapy, S96
 granuloma, due to *Propionibacterium acnes*, 219
 transplantation
 endocarditis in, due to *Propionibacterium acnes*, 224
Scopulariopsis brevicaulis infections in, 820

Staphylococcus aureus infections in, methicillin-resistant, 322
 trovafloxacin effects on, 400
 Loperamide, for diarrhea, protease inhibitor-associated, 908
 Low-density lipoprotein-receptor-related protein, inhibition, antiretroviral agents in, S135
 Lumbosacral plexopathy, in tuberculosis, 116
 Lyme disease
 organism detection in, 166
 serological testing methods, 545
 treatment [letter], 237, 410
 vaccination, May News and Events
 in transplantation, 857
 Lymphadenitis
 due to *Aspergillus*, practice guidelines, 696
 due to *Haemophilus aphrophilus*, 627
 due to *Mycobacterium bohemicum*, 210
 Lymphadenopathy
 in HIV infection, primary, in African women, 486
 in mycobacterial infections, 29
 due to *Sporothrix schenckii*, practice guidelines, 684
 in West Nile virus infections, 413
 Lymphoepithelial lesions, parotid gland, malignant transformation, in HIV infection, 947
 Lymphoma
 in HIV infection, 491, 947
 inflammatory pseudotumor resembling, 826
 prevention with acyclovir, 757, 762
 immunorestitution disease in, 882
 in kidney transplantation, Epstein-Barr virus detection in, 576

Malaria
 aspergillosis with, 938, 940
 in HIV infection, HIV antibody testing in, 819
 neurologic disorders in, causes [letter], 836
 Malignant hyperthermia, in critical illness, evaluation [letter], 234
 Malnutrition
 cytomegalovirus infections in, with *Bordetella bronchiseptica* infections [letter], 408
Streptococcus pneumoniae infections in, 319
 Managed care, home intravenous antibiotic program financial impact, 639
 Measles, vaccination, in transplantation, 857
 Mediastinitis
 due to *Candida*, practice guidelines, 662
 due to *Histoplasma capsulatum*, practice guidelines, 688
 due to *Leishmania donovani*, 764
 Melioidosis, treatment [letter], 235
 Meningitis
 due to *Aspergillus*, practice guidelines, 696
 due to *Candida*, practice guidelines, 662
 due to *Coccidioides immitis*, practice guidelines, 658
 due to *Cryptococcus neoformans*, practice guidelines, 710
 due to herpes simplex virus, immunogenetic determinants, 176
 due to *Histoplasma capsulatum*, practice guidelines, 688
 lipoid, after autologous fat graft necrosis, 613
 Mollaret's, immunogenetic determinants, 176
 due to *Neisseria meningitidis*, resistance in, 212
 due to *Neisseria subflava*, 615
 due to *Peptostreptococcus micros*, 622
 postoperative, diagnosis [letter and reply], 836
 due to *Pseudallescheria boydii*, treatment with voriconazole, 981
 due to *Rhodococcus equi*, treatment, 223
 due to *Sporothrix schenckii*, practice guidelines, 684
 due to *Streptococcus intermedius*, 396

- due to *Streptococcus pneumoniae*
 - penicillin-resistant, 78
 - serogroups in, vaccine implications, 122
- due to viridans streptococci [letter and reply], 238
- Meningococcal infections (see *Neisseria meningitidis* infections)
- Meningoencephalitis, due to *Chlamydia pneumoniae*, 209
- Menstrual cycle, vaginal condition variation in, 901
- Methicillin, resistance to, *Staphylococcus aureus* (see *Staphylococcus aureus* infections, methicillin-resistant)
- Methylobacterium mesophilicum* infections, catheter-related, case report, 936
- Metronidazole, for Crohn's disease, psychiatric symptoms due to, 213
- Microbiology update
 - fastidious bacteria, 166
 - susceptibility testing, 798, 799
- Military forces
 - cough illness causes in, 534
 - sexually transmitted diseases in
 - chlamydial infections, 742
 - gonorrhea, 742
 - historical background, 719
 - prevention of, 730
 - risk behavior and, 723, 730
 - urethritis in, 736
- Streptococcus pneumoniae* vaccination in, 157
- Minocycline, for neuroborreliosis [letter], 237, 410
- Mollaret's meningitis, immunogenetic determinants, 176
- Moraxella osloensis* infections, bacteremia, 179
- Mortality
 - Bacteroides* infections, 870
 - endocarditis, in bicuspid aortic valve, 336
 - Enterococcus faecium* bacteremia, vancomycin-resistant, 466
 - funguria, 14
 - β-hemolytic streptococcal endocarditis, 624
 - histoplasmosis, in HIV infection, 877
 - HIV infection, with hepatitis C [letter and reply], 409
 - methicillin-resistant *Staphylococcus aureus* infections, 322, 368
 - plague, cat-associated, 893
 - Saksenaea vasiformis* infections, 942
 - stereotactic brain biopsy, in HIV infection, 491
 - sudden infant death syndrome, due to *Pneumocystis carinii* [letter], 991
- Mucormycosis, due to *Saksenaea vasiformis*, 942
- Mucosal vaccination, tuberculosis, purified protein derivative hypersensitivity response to, S217
- Mucositis, in bone marrow transplantation, *Stentotrophomonas malophilia* infections in, 195
- Multidrug resistance (see Drug resistance, multiple)
- Multiple myeloma, aspergillosis in, 41
- Mumps, vaccination, in transplantation, 857
- Myalgia
 - due to antiretroviral agents, S96
 - in HIV infection, primary, in African women, 486
 - in West Nile virus infections, 413
- Mycobacterial infections
 - immunorestitution disease in, 882
 - nontuberculous, lymphadenopathy in, 29
- Mycobacterium*, nontuberculous, tuberculosis vaccination and, S262
- Mycobacterium avium* complex infections
 - in HIV infection
 - prophylaxis, S1, S15, S29, S66
 - recurrence after therapy, 511
- immunorestitution disease in, 882
- intestinal, in heart transplantation, 603
- treatment, with clarithromycin-including regimens, 288
- Mycobacterium boemicum* infections, lymphadenitis in, 210
- Mycobacterium bovis*
 - aerosol challenge, in bacille Calmette-Guérin vaccination evaluation, S299
 - MPB83 antigen, in vaccines, S283
 - strain BCG (See Bacille Calmette-Guérin)
- Mycobacterium bovis* infections
 - vs. bacille Calmette-Guérin vaccination, S291
 - from chemotherapy solution contamination, 356
 - transmission to humans, S291
- Mycobacterium fortuitum* infections, endocarditis, 605
 - treatment, 629
- Mycobacterium kansasii* infections, in cancer, 965
- Mycobacterium terrae* infections
 - case reports and literature review, 444
 - in HIV infection, 831
- Mycobacterium tuberculosis* (see also Tuberculosis)
 - aerosol challenge, in bacille Calmette-Guérin vaccination evaluation, S299
 - antigens
 - for immunologic diagnosis, S243
 - in vaccine development, S254
 - ESAT-6 antigen, T lymphocyte recognition, S201
 - genome sequence, vaccine development and, S254
 - identification, for vaccine trials, S276
 - interferon-γ response to, S279
 - Mycobacterium vaccae*, inactivated, for tuberculosis vaccination, in HIV infection, S309
- Mycoplasma pneumoniae* infections
 - cough in, 387
 - organism detection in [letter and reply], 405
- Mycotic aneurysm
 - due to *Chlamydia pneumoniae*, 946
 - due to *Staphylococcus aureus*, in dialysis, 823
- Myelitis
 - due to *Mycoplasma pneumoniae*, organism detection in [letter and reply], 405
 - in tuberculosis, 915
- Myocarditis, due to *Aspergillus*, practice guidelines, 696
- Nail disorders, due to *Candida*, practice guidelines, 662
- Nausea, due to antiretroviral agents, S96
- Neck, lymphadenitis
 - due to *Haemophilus aphrophilus*, 627
 - due to *Mycobacterium boemicum*, 210
- Necrotizing fasciitis
 - due to bananas, e-mail hoax, April News and Events
 - due to *Clostridium difficile*, 954
 - due to *Klebsiella pneumoniae* [letter], 989
- Neisseria gonorrhoeae* infections
 - in military, 736, 742
 - susceptibility testing, 799
 - treatment, with quinolones, 243
- Neisseria meningitidis* infections
 - bacteremia, fulminant, coagulopathy markers in, 643
 - pneumonia, case reviews for 25-year period, 87
 - resistance in, in 1997, 212
 - vaccination
 - in college students, 648
 - in transplantation, 857

Neisseria subflava infections, meningitis, 615
Nelfinavir, for HIV infection, S160
 adverse effects, S96
 in drug combinations, S123, S160
 pharmacodynamics, S151
Neonatal infections
 candidiasis, practice guidelines, 662
 due to herpes simplex virus, vaccination, 549
 due to streptococci group B, invasive, surveillance for, 276
Nephrolithiasis, due to antiretroviral agents, S96
Neuroborreliosis, treatment [letter], 237, 410
Neurologic disorders
 due to antiretroviral agents, S96
 in enterovirus 71 infections, treatment [letter], 988
 in herpes simplex virus infections, vaccination, 549
 in HIV infection, vs. cerebrospinal fluid viral load, 962
 in malaria, causes [letter], 836
 in tuberculosis, 915
Neurosyphilis, in HIV infection, treatment, 540
Neutropenia
 antifungal prophylaxis in, 300
 due to antiretroviral agents, S96
 in bone marrow transplantation, *Stentotrophomonas maltophilia* infections in, 195
 candidiasis prophylaxis in, practice guidelines, 662
 fever in, treatment, with quinolones, 243
 in HIV infection, 256
 zygomycosis in, 851
Neutrophil(s), dysfunction, in HIV infection, 256
Nevirapine, for HIV infection
 adverse effects, S96
 in drug combinations, S123, S130
 resistance to, S185
Nose, pressures within, during blowing, sneezing, and coughing, sinusitis and, 387
Nosocomial infections (see also Catheter-related infections)
 due to *Aspergillus* [letter], 984
 bacteremia
 contaminants vs. true pathogens in [letter], 986
 due to *Staphylococcus aureus* infections, methicillin-resistant, pathogenic significance, 368
 control, hand disinfection in [letter], 990
 due to *Enterobacter cloacae*, 35
 epidemiology, in rehabilitation unit, 425
 due to hepatitis C virus, in health care workers, May News and Events
 due to *Klebsiella pneumoniae*, 55
 meningitis, due to *Rhodococcus equi*, treatment, 223
Mycobacterium bovis infections, from chemotherapy solution contamination, 356
 ocular, in bacteremia, 306
 sporotrichosis, 255, 380
 urinary, due to fungi, 14
 zygomycosis, in cancer center, 851
Nystatin, for candidiasis, practice guidelines, 662
Oat bran, for diarrhea, protease inhibitor-associated, 908
Occupational exposures, to opportunistic infections, prophylaxis, S29
Ocular lesions (see Eye infections)
Ofloxacin
 for *Escherichia coli* infections, adverse effects, 395
 state-of-the-art, 243
Ommaya reservoir, *Coccidioides immitis* hyphal forms in, 349
Onychomycosis, due to *Candida*, practice guidelines, 662
Opportunistic infections, in HIV infection (see also specific diseases)
 epidemiology, S5
 prevention
 adherence to, S15
 adverse effects, S15
Bartonella, S29
 behavioral modifications in, S15
 cost issues in, S15
 discontinuation, S66
 fungal, S1, S29
 practice guidelines, S15, S29
 hepatitis A, S15, S29
 hepatitis B, S15, S29
 hepatitis C, S1, S29, S77
 human herpesvirus 8, S72
 interactions in, S15
Mycobacterium avium complex, S1, S15, S29, S66
 in pediatric patients, S15
 performance measures, S85
Pneumocystis carinii, S1, S15, S29, S66
 in pregnancy, S15, S29
 respiratory, S1
Salmonella, S29
Streptococcus pneumoniae, S29
 toxoplasmosis, S29, 602
 tuberculosis, S1, S29
 viral, S1
Oral infections
 due to *Candida*, practice guidelines, 662
 due to herpes simplex virus, vaccination, 549
Oral vaccination, tuberculosis, purified protein derivative hypersensitivity response to, S217
Osteomyelitis
 due to *Aspergillus*, practice guidelines, 696
 due to *Candida*, practice guidelines, 662
 due to *Sporothrix schenckii*, practice guidelines, 684
 due to *Staphylococcus aureus*, treatment with ceftriaxone, 205
Otitis media, due to *Streptococcus pneumoniae*, serogroups in, vaccine implications, 122
Outbreaks
Coccidioides immitis infections, in returned travelers, 61
 dengue fever, March News and Events
Klebsiella pneumoniae infections, multidrug-resistant, 55
 prediction, satellite technology in, April News and Events
 Q fever, 214
Streptococcus pneumoniae infections, serotype 1, 319
 West Nile virus infections, 413
Pancreatitis
 due to antiretroviral agents, S96
 due to *Candida*, practice guidelines, 662
Pancrelipase, for diarrhea, protease inhibitor-associated, 908
Parainfluenza virus infections
 immunorestitution disease in, 882
 vaccination, in transplantation, 857
Paranasal sinusitis (see Sinusitis)
Parapharyngeal abscess, in cat-scratch disease, 599
Paraspinal abscess, due to *Peptostreptococcus micros*, 622
Paronychia, due to *Candida* practice guidelines, 662
Parotid gland, lymphoepithelial lesions, in HIV infection, malignant transformation, 947
Parvovirus B19 infections, Raynaud's phenomenon in, 500

Pediatric patients
GB virus C/hepatitis G virus infections in, epidemiology, 569
Giardia lamblia carriage in, 419
hepatitis C in, treatment, 585
human immunodeficiency virus infection in
 opportunistic infection prophylaxis in, S15, S29, S85
 rabies vaccination in, 218
 treatment, adherence to, S171
malnutrition in, cytomegalovirus infections in [letter], 408
Staphylococcus aureus infections in, methicillin-resistant, clonal features, 630
streptococcal infections, group B, recurrent, in twins, 282
streptococci group B infections in, invasive, surveillance for, 276
Streptococcus pneumoniae colonization in, 191
Streptococcus pneumoniae pneumonia in, influenza impact on, 784
transplantation in, vaccination in, 857
 Penicillin(s)
 for *Neisseria meningitidis* pneumonia, case reviews for 25-year period, 87
 for neurosyphilis, in HIV infection, 540
 resistance to, *Streptococcus pneumoniae*, 78, 520
 in colonized infants, 191
 surveillance for, 454
 for syphilitic uveitis, 479
 Pentamidine, prophylactic, for opportunistic infections, S25, S29
Peptostreptococcus micros infections, paraspinal abscess, 622
 Pericarditis
 due to *Aspergillus*, practice guidelines, 696
 due to *Candida*, practice guidelines, 662
 due to *Histoplasma capsulatum*, practice guidelines, 688
 Peripheral neuropathy, due to antiretroviral agents, S96
 Peritonitis
 due to *Aspergillus*, practice guidelines, 696
 due to *Candida*, practice guidelines, 662
 due to *Coccidioides immitis*, 971
 due to herpes simplex virus [letter], 839
 Pertussis
 cough in, in military population, 387
 treatment, with erythromycin, February News and Events
 vaccination
 applications to tuberculosis vaccination, S302
 in transplantation, 857
 Pharyngitis, due to herpes simplex virus, vaccination, 549
 Phlebitis, due to *Candida*, practice guidelines, 662
 Plague
 cat-associated, 893
 vaccination, 843
Plasmodium falciparum malaria, aspergillosis with, 938, 940
 Platelet count, in fulminant *Neisseria meningitidis* infections, 643
 Pleural effusion, in voluntary cough suppression, 572
 Pleural infections, due to *Aspergillus*, practice guidelines, 696
 Pneumococcal, due to fungi, 215
Pneumococcal infections (see Streptococcus pneumoniae infections)
Pneumocystis carinii infections
 in HIV infection
 central nervous system, treatment, 397
 diagnosis, 141
 prophylaxis, S1, S15, S29, S66
 immunorestitution disease in, 882
 sudden infant death syndrome in [letter], 991
 Pneumonia
 due to *Aspergillus*, in malaria, 938
 due to *Blastomyces dermatitidis*, practice guidelines, 679
 due to *Candida*, treatment, practice guidelines, 662
 due to *Coccidioides immitis*, practice guidelines, 658
 due to combined cytomegalovirus and *Bordetella bronchiseptica*, in malnutrition [letter], 408
 due to *Coxiella burnetii*, 214
 due to *Cryptococcus neoformans*, practice guidelines, 710
 due to *Haemophilus influenzae*, in HIV infection, 461
 due to *Legionella dumoffii*, organism detection in, 382
 due to *Mycobacterium kansasii*, in cancer, 965
 due to *Neisseria meningitidis*, case reviews for 25-year period, 87
 due to *Pneumocystis carinii*, in HIV infection, diagnosis, 141
 due to rhinovirus, 611
 due to *Sporothrix schenckii*, practice guidelines, 684
 due to *Staphylococcus aureus*, methicillin-resistant, in liver transplantation, 322
 due to *Streptococcus intermedius*, with brain involvement, 396
 due to *Streptococcus pneumoniae*
 Fc_{RIIIa}-R131 allotype and, 25
 influenza impact on, 784
 penicillin-resistant, outcome, 520
 serogroups vs. disease severity and manifestations, vaccine implications, 100, 122
 treatment [letter and reply], 234
 treatment, with quinolones, 243
 viral, immunorestitution disease in, 882
 Poliomyelitis, vaccination, in transplantation, 857
 Polymerase chain reaction
 for *Chlamydia trachomatis*, in screening program [letter and reply], 406
 for herpes simplex virus, in meningitis, 176
 for *Legionella dumoffii*, 382
 for *Mycobacterium bovis*, in contaminated chemotherapy solutions, 356
 for *Pneumocystis carinii*, in HIV infection, 141
 Portosystemic shunts, bacteremia due to, 384
 Potassium iodide solution, for sporotrichosis, 684
 Practice guidelines (see *Infectious Diseases Society of America, practice guidelines*)
 Pregnancy
 chloramphenicol use in [letter], 237
 herpes simplex virus infections in, type 2, amniotic fluid viral load in, 363
 histoplasmosis in, practice guidelines, 688
 HIV infection in, opportunistic infection prophylaxis in, S15
 streptococci group B infections in, invasive, surveillance for, 276
 Prescription drugs, direct-to-consumer advertising, June News and Events
Prevotella, vaginal colonization, variation with menstrual cycle, 901
 Progressive multifocal leukoencephalopathy
 in HIV infection
 brain biopsy in, 491
 treatment, 95
 treatment [letter], 234
 Prophylaxis
Bartonella infections, in HIV infection, S29
 candidiasis
 in HIV infection, S29
 practice guidelines, 662
 coccidioidomycosis, in HIV infection, S29
 cryptococcosis, in HIV infection, S29
 cryptosporidiosis, in HIV infection, S29
 cytomegalovirus infections, in HIV infection, S1, S15, S29
 foodborne diseases, in HIV infection, S29

fungal infections
 in HIV infection, S1, S15
 in neutropenia, 300

gastrointestinal infections, in HIV infection, S29

hepatitis A, in HIV infection, S15, S29

hepatitis B, in HIV infection, S15, S29

hepatitis C, in HIV infection, S1, S29

herpes simplex virus infections, in HIV infection, S1, S29

histoplasmosis, in HIV infection, S29

human herpesvirus 8 infections, in HIV infection, S1

human papillomavirus infections, in HIV infection, S29

influenza
 in HIV infection, S15, S29
 zanamivir for, 587

Kaposi's sarcoma, in HIV infection, S1

lymphoma, in HIV infection, 757, 762

Mycobacterium avium complex infections, in HIV infection, S1, S15, S29, S66

opportunistic infections in HIV infection (see Opportunistic infections, in HIV infection, prevention)

Pneumocystis carinii infections, in HIV infection, S1, S15, S29, S66

respiratory infections, in HIV infection, S1, S15, S29

Salmonella infections, in HIV infection, S29

sexually transmitted diseases, in HIV infection, S29

Streptococcus pneumoniae infections, in HIV infection, S15, S29

toxoplasmosis, in HIV infection, S29, 602

travelers' diseases, in HIV infection, S29

tuberculosis, in HIV infection, S29

varicella-zoster infections, in HIV infection, S1, S29

waterborne diseases, in HIV infection, S29

Propionibacterium acnes infections

endocarditis, in liver transplantation, 224

hepatic granuloma, 219

Prostatitis, due to *Histoplasma capsulatum*, 595

Prosthetic valve infections, due to *Mycobacterium fortuitum*, treatment, 629

Protease inhibitors, for HIV infection (see also specific drugs)
 adverse effects, S96, S135, S160
 clinical studies, S160
 in drug combinations, S160
 drug regimens sparing, S130
 failure, S160
 pharmacodynamics, S151
 research on, S160

Protozoan infections, nonpathogenic, reporting practice guidelines for, 401

Pseudallescheria boydii infections, meningitis, treatment with voriconazole, 981

Pseudomonas aeruginosa infections
 bacteremia, antibiotic susceptibility surveillance, 454
 endocarditis, in injection drug users, 374
 in rehabilitation unit, 425
 resistance in, 454

Pseudotumor, inflammatory, in HIV infection, treatment with thalidomide, 826

Psychiatric disorders, due to metronidazole, 213

Psyllium, for diarrhea, protease inhibitor-associated, 908

Purified protein derivative, delayed hypersensitivity to, mucosal bacille Calmette-Guérin effects on, S217

Pyrazinamide, prophylactic, for opportunistic infections, S25

Pyrimethamine, prophylactic, for opportunistic infections, S25, S29

Q fever
 endocarditis in, *Bartonella* cross-reactivity in, 609
 outbreaks, 214
 vaccination, 843

QT interval, June News and Events

Quinolones
 new, March News and Events
 prophylactic, for opportunistic infections, S29
 resistance to, 454
 state-of-the-art, 243

Quinupristin/dalfopristin, for *Enterococcus faecium* infections
 failure, 403
 vancomycin-resistant, 790

Rabbit fever (see Tularemia)

Rabies
 state-of-the-art, 4
 vaccination
 in HIV infection, 218
 in transplantation, 857

Radial artery harvest site, infections, risk factors for, 270

Radiculomyelitis, in tuberculosis, 915

Ranitidine, for *Helicobacter pylori* infections, serologic evaluation after, 976

Raynaud's phenomenon, in parvovirus B19 infections, 500

Rehabilitation, nosocomial infections in, epidemiology, 425

Resistance (see Drug resistance)

Respiratory failure, in histoplasmosis, in HIV infection, 877

Respiratory infections (see also Pneumonia; Tuberculosis)
 due to *Aspergillus*
 in malaria, 938, 940
 in multiple myeloma, 41
 practice guidelines, 696
 due to *Blastomyces dermatitidis*, practice guidelines, 679
 due to *Coccidioides immitis*
 outbreak in returned travelers, 61
 practice guidelines, 658
 due to *Coxiella burnetii*, 214
 due to *Cryptococcus neoformans*, practice guidelines, 710
 due to *Histoplasma capsulatum*, practice guidelines, 688
 in HIV infection, prophylaxis, S1, S15, S29
 due to *Leishmania donovani*, 764
 in military forces, causes, 534
 due to *Mycobacterium avium* complex
 treatment with clarithromycin-including regimens, 288
 in voluntary cough suppression, 572
 due to *Mycobacterium bovis*, from chemotherapy solution contamination, 356
 due to *Mycobacterium kansasii*, in cancer, 965
 due to *Mycobacterium terrae*, 444
 due to *Sporothrix schenckii*, practice guidelines, 684
 treatment with quinolones, 243

Respiratory syncytial virus infections, vaccination, in transplantation, 857

Retinal lesions, in bacteremia, 306

Retinitis
 due to cytomegalovirus, in HIV infection, 182
 due to *Treponema pallidum*, 479

Reverse-transcriptase inhibitors
 nonnucleoside, for HIV infection (see also specific drugs)
 adverse effects, S96
 protease inhibitors with, S160

- resistance to, S185
- nucleoside, for HIV infection (*see also specific drugs*)
 - adverse effects, S96
 - hydroxyurea with, S193
 - protease inhibitors with, S160
 - resistance to, S185
- Rheumatic disease, in parvovirus B19 infections, 500
- Rhinovirus infections, pneumonia, 611
- Rhodococcus equi* infections, meningitis, treatment, 223
- Rhodotorula rubra* infections, prophylaxis, in neutropenia, 300
- Ribavirin, for hepatitis C, in pediatric patients, 585
- Ricin toxin, vaccination, 843
- Rifabutin
 - for *Mycobacterium avium* complex infections, 288
 - prophylactic, for opportunistic infections, S25, S29
 - for tuberculosis in HIV infection, 779
- Rifalizil, for tuberculosis, animal model, S288
- Rifampin, prophylactic, for opportunistic infections, S25, S29
- Ritonavir, for HIV infection, S160
 - adverse effects, S96, S135
 - in drug combinations, S123, S160
 - pharmacodynamics, S151
 - resistance to, S185
- Rotavirus infections
 - diarrhea
 - in Swedish adults, 770
 - vaccination, in transplantation, 857
- Roth's spots, in bacteremia, 306
- Rubella, vaccination, in transplantation, 857
- Saksenaea vasiformis* infections, mucormycosis, 942
- Salmonella* infections
 - diarrhea
 - in Swedish adults, 770
 - in HIV infection, prophylaxis, S29
 - non-typhoid, bacteremia, age-related differences [letter and reply], 239
 - Salmonella typhimurium* infections, brain abscess, 621
 - Saquinavir, for HIV infection, S160
 - adverse effects, S96, S135
 - in drug combinations, S123, S160
 - pharmacodynamics, S151
- Satellite technology, in outbreak prediction, April News and Events
- Scopulariopsis brevicaulis* infections, subcutaneous, in liver transplantation, 820
- Semmelweis principles, of hand disinfection [letter], 990
- SENTRY Antimicrobial Surveillance Program, results for 1997 and 1998, 454
- Septic arthritis
 - due to *Candida*, practice guidelines, 662
 - due to *Clostridium*, 590
- Septic shock, in *Saksenaea vasiformis* infections, 942
- Septicemia (*see* Bacteremia)
- Sexually transmitted diseases (*see also specific diseases*)
 - in HIV infection, prophylaxis, S29
 - in military
 - chlamydial infections, 742
 - gonorrhea, 742
 - historical background, 719
 - prevention of, 730
 - risk behavior and, 723, 730
 - urethritis in, 736
 - susceptibility to, menstrual cycle and, 901
- treatment, with quinolones, 243
- Shiga toxin-producing *Escherichia coli* infections, urinary tract, hemolytic-uremic syndrome in, 395
- Shigella* infections
 - diarrhea
 - in Swedish adults, 770
 - resistance in, 515
- Shock
 - in histoplasmosis, in HIV infection, 877
 - septic, in *Saksenaea vasiformis* infections, 942
- Shunts
 - portosystemic, bacteremia due to, 384
 - ventriculoperitoneal, *Coccidioides immitis* hyphal forms in, 349
- Sinusitis
 - due to *Aspergillus*
 - in multiple myeloma, 41
 - practice guidelines, 696
 - due to fungi, pneumocephalus in, 215
 - noise blowing impact on, 387
 - treatment, with quinolones, 243
- Skin lesions
 - due to *Alternaria*, 13, 174
 - due to antiretroviral agents, S96
 - due to *Aspergillus*, practice guidelines, 696
 - due to *Candida*, practice guidelines, 662
 - due to combined cytomegalovirus and *Bordetella bronchiseptica*, in malnutrition [letter], 408
 - due to herpes simplex virus, vaccination, 549
 - in HIV infection, primary, in African women, 486
 - larva migrans, treatment, 811
 - due to *Mycobacterium bovis*, from chemotherapy solution contamination, 356
 - due to *Leishmania*, epidemiology, East Timor [letter], 840
 - due to nontuberculous mycobacteria, 29
 - due to *Scopulariopsis brevicaulis*, in liver transplantation, 820
 - due to *Sporothrix schenckii*, 255, 380
 - in Peru, 65
 - practice guidelines, 684
 - treatment, with quinolones, 243
 - in tuberculosis, 201
 - in West Nile virus infections, 413
- Skin tests, for *Coccidioides immitis*, in California, 612
- Sleep disorders, due to antiretroviral agents, S96
- Smallpox vaccination, as bioterrorism protection, 843, May News and Events
- Soft-tissue infections (*see also* Cellulitis)
 - due to *Clostridium difficile*, 954
 - due to *Haemophilus aphrophilus*, 627
 - due to *Scopulariopsis brevicaulis*, in liver transplantation, 820
 - treatment, with quinolones, 243
- SP-303, for diarrhea, protease inhibitor-associated, 908
- Sparfloxacin
 - state-of-the-art, 243
 - for *Streptococcus pneumoniae* pneumonia [letter and reply], 234
- Specialists, in infectious diseases, impact [letter and reply], 838
- Spinal cord
 - herpes simplex virus infections, vaccination, 549
 - injury, rehabilitation, nosocomial infection epidemiology in, 425
 - Mycoplasma pneumoniae* infections, organism detection in [letter and reply], 405
 - tuberculosis manifestations in, 915
- Spine
 - abscess, due to *Peptostreptococcus micros*, 622

echinococcal cyst, 442, 567

Splenomegaly, in HIV infection, 943

Sporotrichosis

- diagnosis, 255, 380
- epidemiology, Peru, 65
- practice guidelines, 684

Staphylococcal enterotoxin B, vaccination, 843

Staphylococcal infections

- coagulase-negative, bacteremia, antibiotic susceptibility surveillance, 454
- endocarditis, in bicuspid aortic valve, 336

Staphylococcus aureus infections

- aortic aneurysm in, in dialysis, 823
- bacteremia

 - antibiotic susceptibility surveillance, 454
 - database on, 633
 - after portosystemic shunt placement, 384

- endocarditis, in injection drug users, 374
- liver abscess, in chronic granulomatous disease, treatment with granulocyte-macrophage colony-stimulating factor, 222

methicillin-resistant

- bacteremia, pathogenic significance, 368
- clonal features, 630
- in liver transplantation, 322
- in rehabilitation unit, 425
- surveillance for, 454
- susceptibility testing, 799
- treatment, with linezolid, 146

osteomyelitis, treatment with ceftriaxone, 205

resistance in, vancomycin, susceptibility testing, 799

virulence factors, in endocarditis, 374

Stavudine, for HIV infection

- adverse effects, S96
- in drug combinations, S123, S143
- hydroxyurea with, S193
- lactic acidosis due to, 198
- resistance to, S185

Stem cells, transplantation, influenza vaccination in, granulocyte-macrophage colony-stimulating factor with, 342

Stentotrophomonas maltophilia infections, bacteremia, in bone marrow transplantation, 195

Stereotactic biopsy, brain lesions, in HIV infection, 491

Stevens-Johnson syndrome, due to antiretroviral agents, S96

Streptococcal infections

- endocarditis, in bicuspid aortic valve, 336
- group B

 - invasive, maternal and neonatal, surveillance for, 276
 - recurrent, in twin infants, 282

- β -hemolytic, endocarditis, mortality in, 624
- susceptibility testing, 799
- toxic shock syndrome in

 - kallikrein-kinin system activation in, 961
 - physician's personal experience, 922

- viridans

 - endocarditis, in bicuspid aortic valve, 336
 - meningitis [letter and reply], 238

Streptococcus agalactiae infections

- invasive, maternal and neonatal, surveillance for, 276
- recurrent, in twin infants, 282

Streptococcus intermedius infections, pneumonia, with brain involvement, 396

Streptococcus pneumoniae

- colonization, penicillin-resistant, 191
- susceptibility testing, 799

Streptococcus pneumoniae infections

- bacteremia, antibiotic susceptibility surveillance, 454
- in HIV infection, prophylaxis, S15, S29
- meningitis, 71
- pneumonia

 - $Fc_{RIIIa}-R131$ allotype and, 25
 - influenza impact on, 784
 - treatment [letter and reply], 234

- resistance in, 71, 520
- serogroups

 - vs. disease severity and manifestations, vaccine implications, 100, 122

- outbreak of type 1, 319

vaccination, 319

- education on, April News and Events
- in military, 157
- in transplantation, 857
- trial design, S206

Streptomycin, resistance to, *Shigella*, 515

Strongyloidiasis, in HIV infection, epidemiology [letter], 241

Sudden infant death syndrome, due to *Pneumocystis carinii* [letter], 991

Sulfadiazine, prophylactic, for opportunistic infections, S29

Sulfisoxazole, resistance to, *Shigella*, 515

Surgical infections

- epidemiology, in rehabilitation unit, 425
- meningitis, diagnosis [letter and reply], 836
- radial artery harvest site, risk factors for, 270

Surveillance

- antibiotic susceptibility, 454
- funguria, 14
- group B streptococcal infections, maternal and neonatal, 276
- outbreak potential, satellite technology in, April News and Events
- West Nile virus, May News and Events

Susceptibility testing (see also Drug resistance)

- Bacteroides*, 870
- fastidious organisms, 799
- Mycobacterium terrae*, 444
- SENTRY surveillance program, 454
- Sweet's syndrome, in mycobacterial infections, 29
- Syphilis

 - in HIV infection, treatment, 540
 - uveitis in, 479

Tenosynovitis, due to *Mycobacterium terrae* 444

Terbinafine

- for *Scopulariopsis brevicaulis* infections, in liver transplantation, 820
- for sporotrichosis, 684

Terconazole, for candidiasis, practice guidelines, 662

Terrorism (see Bioterrorism)

Tetanus, vaccination, in transplantation, 857

Tetracycline, resistance to, *Shigella*, 515

Thalidomide, for inflammatory pseudotumor, in HIV infection, 826

Thiabendazole, for cutaneous larva migrans, 811

Thrombopoietin, measurement, in fulminant *Neisseria meningitidis* infections, 643

Tick-borne encephalitis, isolated initial phase [letter], 987

Tioconazole, for candidiasis, practice guidelines, 662

Tipranavir, for HIV infection, S160

T lymphocytes

- bacille Calmette-Guérin response, S257

in HIV infection (see Human immunodeficiency virus infection, T lymphocytes in)

Mycobacterium tuberculosis ESAT-6 antigen response, S201

Mycobacterium tuberculosis response, S257

Tobramycin, extended-interval dosing, national survey, 433, 440

Tonate virus infections, encephalitis, 188

Toxic shock syndrome, streptococcal

- kallikrein-kinin system activation in, 961
- physician's personal experience, 922

Toxoplasmosis, in HIV infection, prophylaxis, S15, S29, 602

Tracheitis, due to *Aspergillus*, practice guidelines, 696

Tracheobronchitis, due to *Aspergillus*, in malaria, 938

Transjugular intrahepatic portosystemic shunt, bacteremia due to, 384

Transplantation

- bone marrow, *Stenotrophomonas maltophilia* bacteremia in, 195
- candidiasis prophylaxis in, practice guidelines, 662
- heart, *Mycobacterium avium* complex intestinal infections in, 603
- immunorestitution disease in, 882
- kidney, lymphoma after, Epstein-Barr virus detection in, 576
- liver

 - Propionibacterium acnes* endocarditis in, 224
 - Scopulariopsis brevicaulis* infections in, 820
 - Staphylococcus aureus* infections in, methicillin-resistant, 322
 - stem cell, influenza vaccination in, granulocyte-macrophage colony-stimulating factor with, 342
 - vaccination in, in pediatric patients, 857

Transverse myelitis, due to *Mycoplasma pneumoniae*, organism detection in [letter and reply], 405

Travelers' diseases

- African trypanosomiasis, case study [letter], 985
- due to *Coccidioides immitis*, 61
- due to *Coxiella burnetii*, 214
- cutaneous larva migrans, treatment, 811
- in HIV infection, prophylaxis, S29
- importance, 809
- interdisciplinary management, 809
- multidrug-resistant tuberculosis, 617
- vaccination, in transplantation, 857

Treponema pallidum infections, uveitis in, 479

Triglycerides, elevation, due to antiretroviral agents, S96

Trimethoprim-sulfamethoxazole

- prophylactic, for opportunistic infections, S25, S29
- resistance to, *Shigella*, 515

Trovafloxacin

- hepatitis due to, 400
- state-of-the-art, 243

Trypanosomiasis, African, case study [letter], 985

Tuberculoma, cerebral, treatment, 625

Tuberculosis

- asymptomatic, diagnosis, S243
- atypical presentations, population-based survey, 293
- aural, treatment, paradoxical reaction in, 625
- diagnosis

 - immunologic, S243
 - in vaccination trial design, S230, S276

- epidemics, control with vaccines, S316
- epidemiology, S233
- in HIV infection

 - prophylaxis, S1, S15, S29
 - treatment with rifabutin, 779

- immunity to, correlates, S279
- immunorestitution disease in, 882

latent, practice guidelines for, February News and Events

lumbosacral plexopathy in, 116

miliary, cutaneous manifestations, 201

radiculomyelitis in, 915

research on, S233

resistance in, multiple, 617

screening for, in sexually transmitted disease clinics [letter], 986

symptoms, population-based survey, 293

transmission, multidrug-resistant strain, 617

treatment, with rifalizil and isoniazid, S288

vaccination

- adjuvants in, S266
- DNA vaccines in, S233, S247, S283
- efficacy

 - aerosol challenge, S299
 - evaluation procedures for, S250, S257, S262, S276
 - in epidemic control, S316

- ESAT-6 antigen and, S201
- geographical effects on, S262
- historical background, S262
- in HIV infection, S309
- ideal vaccine for, S233
- immunologic diagnosis before, S243
- mouse models, S283
- mucosal, S217
- Mycobacterium bovis* antigen MPB83 in, S283
- Mycobacterium bovis* infection vs. bacille Calmette-Guérin, S291
- Mycobacterium vaccae* in, S309
- national developmental strategy for, S233
- new products for, S254
- pertussis vaccination experience and, S302
- pneumonia vaccine information applied to, S206
- primate model for, S210
- protective immunity correlates, S279
- regulatory procedures for, S247
- trials, S213

 - clinical considerations in, S230
 - ethical issues in, S266
 - veterinary, S222, S283, S291

Tularemia

- ataxia in, 211
- endocarditis in, 399
- organism detection in, 166
- vaccination, 843

Ultrace MT 20, for diarrhea, protease inhibitor-associated, 908

United States Public Health Service, opportunistic infection prevention practice guidelines (see Opportunistic infections, in HIV infection, prevention)

Ureaplasma urealyticum infections, in military, 736

Urethritis

- due to herpes simplex virus, screening for, 982
- in military, 736

Urinary tract infections

- due to *Aspergillus*, practice guidelines, 696
- due to *Candida*, practice guidelines, 662
- epidemiology, in rehabilitation unit, 425
- due to *Escherichia coli*, Shiga toxin-producing, hemolytic-uremic syndrome in, 395
- due to fungi, surveillance, 14
- recurrent, in postmenopausal women, 152
- treatment, with quinolones, 243

Urine

Legionella dumoffii detection in, 382
 retention of, recurrent infections in, 152
Uveitis, due to *Treponema pallidum*, 479

Vaccines and vaccination
 adjuvants for, S266
 anthrax, 843
bacille Calmette-Guérin (*see* *Bacille Calmette-Guérin*, vaccination with)
 for bioterrorism, 843
 botulism, 843
Brucella, 843
Coxiella burnetii, 843
cytomegalovirus, in transplantation, 857
diphtheria, in transplantation, 857
Epstein-Barr virus, in transplantation, 857
Haemophilus influenzae
 in transplantation, 857
 trial design, S206
hepatitis A, in transplantation, 857
hepatitis B, in transplantation, 857
herpes simplex virus
 review article, 549
 in transplantation, 857
in HIV infection, for opportunistic infections, S15
influenza
 in stem cell transplantation, granulocyte-macrophage colony-stimulating factor with, 342
 in transplantation, 857
Lyme disease, May News and Events
 in transplantation, 857
measles, in transplantation, 857
mumps, in transplantation, 857
Neisseria meningitidis
 in college students, 648
 in transplantation, 857
parainfluenza virus, in transplantation, 857
pertussis
 applications to tuberculosis vaccination, S302
 in transplantation, 857
plague, 843
poliomyelitis, in transplantation, 857
Q fever, 843
rabies, 4
 in HIV infection, 218
 in transplantation, 857
respiratory syncytial virus, in transplantation, 857
ricin toxin, 843
rotavirus, in transplantation, 857
rubella, in transplantation, 857
smallpox, May News and Events, 843
staphylococcal enterotoxin B, 843
Streptococcus pneumoniae, 319
 education on, April News and Events
 in military, 157
 serogroup considerations, 100, 122
 in transplantation, 857
 trial design, S206
tetanus, in transplantation, 857
 in transplantation, in pediatric patients, 857
travelers' diseases, in transplantation, 857

tuberculosis (*see* *Tuberculosis*, vaccination)
tularemia, 843
varicella-zoster virus, in transplantation, 857
Venezuelan equine encephalitis, 843

Vagina
 candidiasis, in primary HIV infection, in African women, 486
 microflora, menstrual cycle variations in, 901

Valacyclovir, prophylactic, for opportunistic infections, S29

Vancomycin
 resistance to (*see* *Enterococcal infections*, *vancomycin-resistant*)
Staphylococcus aureus, 799
 for *Streptococcus pneumoniae* infections, cefotaxime-resistant, 71

Varicella-zoster virus infections
 facial nerve palsy in, 529
 in HIV infection, prophylaxis, S1, S29
 vaccination, in transplantation, 857

Vasculitis, in parvovirus B19 infections, 500

Venezuelan equine encephalitis
 tonate virus subtype of, 188
 vaccination, 843

Ventriculoperitoneal shunts, *Coccidioides immitis* hyphal forms in, 349

Viridans streptococcal infections
 endocarditis, in bicuspid aortic valve, 336
 meningitis [letter and reply], 238

Virulence factors, *Streptococcus pneumoniae*, Fc_{RIIIa}-R131 allo-types and, 25

Visceral leishmaniasis, natural history, in Brazil, 608

Voriconazole, for *Pseudallescheria boydii* meningitis, treatment with voriconazole, 981

Waterborne diseases
 due to *Escherichia coli*, hemolytic-uremic syndrome in [letter and reply], 984
 in HIV infection, prophylaxis, S29

Weakness, in West Nile virus infections, 413

Weight loss
 in histoplasmosis, 595
 in tuberculosis, population-based survey, 293

West Nile virus infections
 mosquito control in, May News and Events outbreaks, 413

White, Arthur C., memorial to, 3

Whooping cough (*see* *Pertussis*)

***Yersinia pestis* infections**
 cat-associated, 893
 vaccination, 843

Zalcitabine, for HIV infection
 adverse effects, S96
 in drug combinations, S123
 hydroxyurea with, S193

Zanamivir, for influenza, prophylactic, 587

Zidovudine, for HIV infection
 adverse effects, S96
 in drug combinations, S123, S130, S160
 hydroxyurea with, S193
 resistance to, S185

Zygomycosis, in cancer center, 851